



**HAL**  
open science

## Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD

Xavier Benarous, Angèle Consoli, Jean-Marc Guilé, Sébastien Garny de La Rivière, David Cohen, Bertrand Olliac

### ► To cite this version:

Xavier Benarous, Angèle Consoli, Jean-Marc Guilé, Sébastien Garny de La Rivière, David Cohen, et al.. Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD. *European Child and Adolescent Psychiatry*, 2016, pp.1-19. 10.1007/s00787-016-0907-5 . hal-01379080

**HAL Id: hal-01379080**

<https://hal.sorbonne-universite.fr/hal-01379080v1>

Submitted on 11 Oct 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

[Click here to view linked References](#)

1  
2  
3 Evidence-based treatments for youths with severely dysregulated  
4  
5  
6 mood: a qualitative systematic review of trials for SMD and DMDD  
7  
8  
9

10  
11  
12 Xavier Benarous<sup>1</sup> [xavierbenarous@gmail.com](mailto:xavierbenarous@gmail.com), Angèle Consoli<sup>1,2</sup> [angele.consoli@psl.aphp.fr](mailto:angele.consoli@psl.aphp.fr), Jean-Marc Guilé<sup>1,3,4</sup>  
13 [guile.jean-marc@chu-amiens.fr](mailto:guile.jean-marc@chu-amiens.fr), Sébastien Garny de La Rivière<sup>3</sup> [garnydelariviere.sebastien@chu-amiens.fr](mailto:garnydelariviere.sebastien@chu-amiens.fr),  
14  
15 David Cohen<sup>1,5</sup> [david.cohen@psl.aphp.fr](mailto:david.cohen@psl.aphp.fr), Bertrand Olliac<sup>1,6</sup> [bertrand.olliac@gmail.com](mailto:bertrand.olliac@gmail.com)  
16  
17  
18

19  
20 <sup>1</sup> Department of Child And Adolescent Psychiatry, Pitié-Salpêtrière Hospital, 47-83 boulevard de l'Hôpital, 75013  
21 Paris, France

22  
23 <sup>2</sup> INSERM U-669, PSIGIAM, Paris, France

24  
25 <sup>3</sup> Groupe de Recherches sur l'Analyse Multimodale de la Fonction Cérébrale, INSERM U1105, CHU, Université  
26 Picardie Jules Verne, Amiens, France

27  
28 <sup>4</sup> Department of Psychiatry, McGill University, Montreal, Canada

29  
30 <sup>5</sup> CNRS UMR 7222, Institute for Intelligent Systems and Robotics-ISIR, Paris, France

31  
32 <sup>6</sup> Pôle Hospitalo-Universitaire de psychiatrie de l'enfant et de l'adolescent, Centre Hospitalier Esquirol, Limoges,  
33 France  
34  
35  
36

37  
38 **Address of correspondence:** Xavier Benarous, Department of Child And Adolescent Psychiatry, Pitié-Salpêtrière  
39 Hospital, 47-83 boulevard de l'Hôpital, 75013 Paris, France

40  
41 **Email:** [xavierbenarous@gmail.com](mailto:xavierbenarous@gmail.com)

42  
43 **Phone:** +33(0)603260193

44  
45 **Fax:** +33(0)142162331

46  
47 **Category:** Review article

48  
49 **Abbreviated title:** Treatments for youths with SMD and DMDD

50  
51 **Conflict of interest:** On behalf of all authors, the corresponding author states that there is no conflict of interest.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## ABSTRACT

1  
2  
3 The aim of this literature review was to examine the evidence for psychotherapeutic and  
4 pharmacological treatments in subjects with severely dysregulated mood and to identify  
5 potential areas for improvements in research designs. A literature search was conducted using  
6 several databases for published (PubMed, PsycINFO) and ongoing (clinical trial registries)  
7 studies conducted in youths who met NIMH's criteria for Severe Mood Dysregulation (SMD)  
8 or the DSM-5 diagnosis of Disruptive Mood Dysregulation Disorder (DMDD). Eight  
9 completed studies were identified: three randomized trials, four open pilot studies and one  
10 case report. Seven ongoing studies were found in trial registries. The available evidence  
11 suggests potential efficacy of psychotherapies which have previously been developed for  
12 internalizing and externalizing disorders. The two main pharmacological strategies tested are,  
13 first, a monotherapy of psychostimulant or atypical antipsychotic such as risperidone, already  
14 used in the treatment of severe irritability in youths with developmental disorders; and  
15 second, the use of a serotonergic antidepressant as an add-on therapy in youths treated with  
16 psychostimulant. Ongoing studies will further clarify the effectiveness of psychotherapeutic  
17 interventions for DMDD individuals and whether they should be given alone or in  
18 conjunction with other treatments. The short duration of the trials for a chronic disorder, the  
19 low number of studies, the lack of placebo or active comparator arm, and restrictive inclusion  
20 criteria in most of the controlled trials dramatically limit the interpretation of the results.  
21 Finally, future research should be conducted across multiple sites, with standardized  
22 procedures to measure DMDD symptoms reduction, and include a run-in period to limit  
23 placebo effect.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

58 **KEYWORDS:** disruptive mood dysregulation disorder; severe mood dysregulation;  
59 psychotherapy; pharmacotherapy; therapeutics; irritability  
60  
61  
62  
63  
64  
65

# 1. INTRODUCTION

## *1.1.General background*

Children with severely dysregulated mood have become diagnostic and therapeutic challenges over the last two decades within the context of pediatric bipolar controversy [1-4]. In view of facilitating research programs researchers at the U.S. National Institute of Mental Health (NIMH) operationalized the criteria of “Severe Mood Dysregulation” (SMD), a syndrome characterized by chronic abnormal levels of anger or sadness, hyperarousal and heightened verbal or physical reactivity [5]. On the grounds of studies conducted in youths with SMD and in view of improving mental health care of youths with chronic irritability, the Disruptive Mood Dysregulation Disorder (DMDD) was introduced as a new diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) within the Depressive Disorders section [6]. Youths with DMDD present chronic irritability combined with severe and recurrent episodes of temper outburst inconsistent with their developmental level at least three times per week and occurring in different settings (e.g., in family, school). These symptoms should persist more than twelve months with no symptom-free period longer than three months and with an initial onset prior to the age of 10. Prevalence of DMDD is reported to be around 8.2% in general population [7-9] and around 26-31% in clinical settings [10,11]. There is much evidence supporting that DMDD symptoms severely affect a youth’s level of social functioning [7,8] and that such negative effects could persist into adulthood [9]. Copeland et al. showed that as adults youths with DMDD present a much higher level of functional impairments (i.e., adverse health outcomes, financial problems, police contact, and low educational attainment) than those with any other psychiatric disorders (e.g., depressive

1 disorders, anxiety disorders, attention deficit hyperactivity disorder ADHD, disruptive disorder,  
2 or substance disorders) [9].  
3  
4  
5  
6

### 7 *1.2. Phenomenology of youths with severely dysregulated mood*

8  
9

10  
11  
12 Mood dysregulation (i.e., severe irritability and high level of anger) is seen as a  
13 transdiagnostic symptom, with a dimensional continuum from its typical expression in normal  
14 development of children and adolescences to severely impairing forms in psychiatric disorders  
15 [12]. In this vein, the development of studies based on specific cognitive and emotional domains  
16 rather than DSM-5 categories of disorders has been encouraged, in particular research aligned  
17 with the framework of the Research Domain Criteria articulated by the NIMH. This strategy  
18 has led to significant improvements in our knowledge of the mechanisms underlying varying  
19 aspects of mood dysregulation in youths. Such progress may ultimately lead to discovering new  
20 markers of the disorder and targets for specific interventions. The study published by Stoddard  
21 et al. [13] provides a good example of how these different levels of analysis can be integrated  
22 in research based on a dimensional view of psychopathology; with the articulation between  
23 impaired neural substrates (i.e., orbitofrontal cortex and amygdala activation), a clinical or  
24 psychological marker (i.e., the result at a face-emotion labelling task), and a therapeutic (i.e.,  
25 computer-based) intervention targeting interpretation bias.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 A different approach has been used in the present review as we specifically focused on  
47 studies where the clinical categories of SMD or DMDD were applied to define the population  
48 of interest. The SMD (i.e., the research syndrome) and then DMDD (i.e., the DMS-5 diagnosis)  
49 criteria were originally developed in view of facilitating the identification of youths with severe,  
50 persistent and functionally impairing forms of irritability, who were likely to fulfil criteria for  
51 different disorders at different times (“diagnostically homeless”) [14]. The development of a  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 specific category for these youths was endorsed due to the need to facilitate access to treatment,  
2 to reduce the rate of misdiagnosis especially early-onset bipolar disorder, and finally to reduce  
3 excessive and inappropriate medication. The inclusion of the DMDD in the 5<sup>th</sup> version of the  
4 DSM has encouraged the development of evidence-based trials which would have been difficult  
5 if mood dysregulation had been operationalized as a dimension. The use of specific disorders  
6 for youths with severely dysregulated mood was encouraged to limit the confusion with early-  
7 onset bipolar disorder and to enhance a more rational use of psychotropic medications (in  
8 particular, mood stabilizers). This issue was regarded as a major public health challenge  
9 considering the trend to overmedication and polypharmacy observed in prepubertal youths [15].  
10 Mood dysregulation can be found in youths with various forms of psychopathology for example  
11 among youths with autistic spectrum disorder and sensory integration issues or in patients with  
12 post-traumatic stress disorder who experience episodic hyperarousal [16]. If a treatment has a  
13 positive impact only in patients with a comorbid psychiatric disorder, its overall benefit in  
14 clinical trial would be under- or overestimated with regards to its prevalence in the sample  
15 studied. The use of a categorical approach can help to explore the heterogeneity of the response  
16 to treatment in DMDD youths, for example through secondary analyses of subgroups with  
17 different associated psychiatric disorders.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 *1.3. Validity of SMD and DMDD diagnoses*

44  
45  
46  
47  
48 Evidence for the validity of SMD and later DMDD diagnosis was raised on the ground of  
49 studies exploring the internal and external validity of these disorders, especially data on  
50 discriminant validity [17,18], familial studies [19], psychophysiological and neuroimaging  
51 studies [20-23], as well as response to pharmacological treatment [24,14]. However, concerns  
52 have been raised regarding different aspects of the diagnostic validity: the paucity of data  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 regarding reliability in literature, the difficulty in delineating the normal and abnormal mood  
2 lability in children, and above all the high rate of overlap with others psychiatric disorders,  
3 especially ADHD and ODD [8,10,11]. In addition, other aspects of child psychopathology are  
4 still rarely taken into consideration in these studies regarding some aspects of a child's  
5 individual characteristics (e.g., temperamental traits and attachment style) and environmental  
6 backgrounds (e.g., parent-child interaction patterns, possibility of co-occurring maltreatment).  
7 Lastly, significant changes were made in the process of integrating the category of SMD in  
8 DSM-5 including removing the criterion of hyperarousal (e.g., insomnia, agitation,  
9 distractibility, racing thoughts/flight of ideas, pressured speech, and intrusiveness), and the  
10 criterion of low intelligence (IQ<80) from the exclusionary criteria, as well as lowering the age  
11 of onset from 12 to 10 years old [6]. Such differences are not trivial and could affect the  
12 comorbidity profiles of SMD and DMDD. For example, despite the lack of direct comparison  
13 between the two clinical entities, data suggests that DMDD most often co-occurs with  
14 depressive disorders and ODD and less with ADHD compared to SMD [10].  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

#### 36 *1.4. Therapeutic strategies*

37  
38  
39  
40

41 Little is known about effective treatments of SMD and DMDD. The DSM-5 Task Force  
42 suggested that “individual therapy, as well as work with the child's family and/or school [and]  
43 the use of medication to help address specific symptoms” could be useful for DMDD youths  
44 [6]. However, the use of treatments targeting symptoms without considering the overall  
45 diagnosis has been criticized as it may contribute to the high rates of polypharmacy in this  
46 population [25-27]. Given that SMD and DMDD frequently occur with comorbid psychiatric  
47 disorders [8,10,11,28-30], it has been suggested that therapeutic interventions should primarily  
48 focus on treating associated disorders. However, studies examining the benefit of  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
psychotherapy or pharmacotherapy on mood dysregulation in different psychiatric disorders are somewhat mixed [31,32]. Galanter et al. [32] found that the higher baseline levels of psychopathology of children with ADHD and mood dysregulation, compared to those without prominent mood dysregulation, persisted after intensive multimodal treatments for ADHD, suggesting the need for additional treatment. In a recent systematic review, Tourian et al. examined empirical evidence supporting the use of pharmacological treatments for severe anger/irritability symptoms in youths [4]. They found that pharmacotherapeutic treatment for both aggression and chronic irritability includes various options, such as antidepressants, especially selective norepinephrine reuptake inhibitors, mood stabilizers, psychostimulants, antipsychotics, and alpha-2 agonists. However, such findings are difficult to generalize, since, as the authors noted, a majority of the study was conducted in small and specific populations (e.g., youths with developmental disorders). Even if no treatment algorithm for severe persistent irritability in youths can be derived from this data, that study can be regarded as a first step for providing evidence-based treatments for children with DMDD as it informed about the potentially effective treatments. However, in view of meeting the needs of clinician and researcher, randomized controlled clinical trials (RCTs) specifically developed for youths with SMD or DMDD are required.

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
The high rates of comorbidity of SMD and DMDD with externalized disorders [8,10,11,28-30] raise questions about the best ways to conduct such trials. How should pharmacological and psychotherapeutic interventions for DMDD be tested within existing therapeutic strategies for externalized disorders? Which treatments should be allowed in the control group? How should the severity of mood symptoms be measured? Is the inclusion of only DMDD subjects without psychiatric comorbidity an acceptable strategy?

### *1.5.Aims of the present review*



1  
2 In this study we performed a systematic review to examine psychotherapeutic and  
3  
4 pharmacological interventions for youths presenting SMD or DMDD. Considering the short  
5  
6 delay since the development of DMDD's criteria, such an exhaustive review was not intended  
7  
8 to determine the comparative efficacy and tolerability of these treatments. Our main aim was  
9  
10 rather to describe the benefits and limitations of different research strategies currently  
11  
12 developed for SMD and DMDD with the aim of guiding future research. In this vein, both  
13  
14 published and ongoing studies are presented in this paper.  
15  
16  
17  
18  
19  
20  
21  
22  
23

## 24 **2. METHODS**

### 25 *2.1. Review*

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37 The systematic review was conducted following the recommendations outlined in the  
38  
39 PRISMA guide (Figure 1) [33]. Titles and abstracts were scanned for relevance. Full texts  
40  
41 were ordered in case of uncertainty to maximize sensitivity. Reference lists of retrieved  
42  
43 systematic reviews were checked. All full texts were checked for eligibility. Any original  
44  
45 study (open trial, double-blind trial whether randomized control or not), case-report, case-  
46  
47 series, meta-analysis and systematic review of pharmacological and non-pharmacological  
48  
49 intervention was eligible for inclusion in this review. Abstracts and editorials were excluded.  
50  
51

52  
53 As DMDD was previously known in the literature under the alias of Severe Mood  
54  
55 Dysregulation (SMD), studies conducted among youths with SMD were included in the  
56  
57 current analysis. Study participants had to be diagnosed with SMD or DMDD, and to be  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 between five and 18 years old, or the mean age of the participants had to fall within the  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

between five and 18 years old, or the mean age of the participants had to fall within the  
aforementioned age range.

[Insert Figure 1, about here]

## 2.2. Search method for identification of studies

Relevant articles for this study were obtained through Cochrane Central Register of Controlled Trials (CENTRAL), Pubmed, Medline, PsychINFO, PsychINDEXplus and Dissertation Abstracts. Each database was searched from January 2001 to December 2015. In addition, we hand searched reference lists of identified articles and pertinent reviews for additional studies. References from the reviewed articles were also screened to find more articles of interest. Furthermore, clinical trials registries (<http://www.clinicaltrials.gov> of the US National Institutes of Health and the WHO International Clinical Trials Registry Platform, ICTRP) were searched for ongoing trials. We used the following search terms: “Disruptive mood dysregulation disorder” OR “Severe mood dysregulation” OR “Temper outburst” AND “Therapeutics” OR “Clinical protocols” OR “Treatment” OR “Pharmacotherapy” OR “Psychotherapy”. Authors independently screened potential studies, after reading the full article, for inclusion in the review, and the results were collated. The systematic review yielded 86 hits, with 29 being a duplicate; 21 hits could be excluded based on the information in the title or abstract. The full texts of 36 hits were critically reviewed leading to exclusion of another 21 articles because these were only reviews or comments and no new original data were included; or the research was not conducted in DMDD/SMD youths. A list of 15 studies was generated: eight completed studies (one case report, four open pilot studies and three RCTs) and seven ongoing studies found in trial registries.

1  
2  
3 *2.3.Data and analysis*  
4  
5  
6  
7

8 Data and information extractions from each study were performed independently by  
9 the two first authors. For each study under review, year of publication and references were  
10 extracted. In order to summarize the treatment attributes in each report we collected the  
11 following information: description of medication, length of treatment, and dose received.  
12 Information on additional or adjunctive interventions was also collected. Additional  
13 information regarding the attributes of participants enrolled in the studies were extracted and  
14 were as follows: age, gender, how the diagnosis was made, treatment setting, comorbid  
15 conditions, sociodemographic data, and screening tools used. Although a meta-analytic  
16 review has been preferable, the diversity of statistical methods and measurement practices  
17 across studies did not allow for the calculation of pooled effect size. We categorized the level  
18 of evidence presented in each paper using the United States Preventive Services Task Force  
19 (USPSTF) criteria [35]. According to this schematic, level I evidence denotes having at least  
20 one well-designed RCT supporting a treatment’s possible efficacy. Level II-1 requires a well-  
21 designed controlled trial without randomization, level II-2 requires at least one well-designed  
22 cohort or case–control study, and level II-3 requires a multiple time series design. We  
23 excluded level III evidence (opinions of respected authorities based on clinical experience or  
24 descriptive studies) from the present review.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

54 **3. RESULTS**  
55  
56  
57

58 *3.1.Psychotherapeutic interventions for DMDD*  
59  
60  
61  
62  
63  
64  
65

### 3.1.1. Completed studies

Only three studies were eligible for the review (Table 1): an exploratory analysis from a controlled study of multiple interventions for ADHD children [36], the subsequent open uncontrolled feasibility study conducted by the same research team on youths with ADHD and SMD [37], and an open pilot uncontrolled study on DMDD youths [13].

Waxmonsky et al. (2008) conducted secondary analysis of data from the 2003-2004 ADHD Summer Treatment Program (ADHD-STP), a research program for children aged 5–12 in the form of an intensive 9-week therapeutic summer camp [38]. The initial study aimed to assess the relative efficacy and synergistic effects of differential doses of behavioural and pharmacologic interventions in ADHD youths. Among the 106 participants 33 fulfilled NIMH criteria for SMD (mean age  $8.0 \pm 2.1$  years and  $8.7 \pm 2.0$  years for non SMD group). The behavioral intervention consisted of daily social skills training and a reward-based learning program (detailed in [39]). This treatment varied in frequency every three weeks with the order: no behavior modification, low-intensity (i.e., weekly sessions) and high-intensity (i.e., daily sessions). Clinicians rating mood symptoms were not blind to treatments status. There was no evidence of differential treatment efficacy or tolerability on ADHD symptoms between the participants with and without SMD, even though those with SMD were more likely to remain significantly impaired at home than non-SMD subjects. After nine weeks, multimodal treatment produced a 34% reduction in YMRS ratings in SMD subjects ( $p < 0.001$ ).

In an open-label uncontrolled rater-blind study, Waxmonsky and colleagues examined the feasibility and preliminary efficacy of a psychotherapeutic program that integrated components of CBT focusing on affect regulation and parent training intervention [37]. The seven included children (mean age  $8.7 \pm 1.6$  years) presented ADHD and the NIMH criteria

1 for SMD. All participants were male. All of the children took stimulant medication for ADHD  
2 and all but two participants were currently receiving counselling services. SMD symptoms  
3  
4 were assessed using the depression and mania modules from the Washington University  
5  
6 Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS). The  
7  
8 sessions consisted of 105-minute concurrent parent and child meetings. Six of the seven  
9  
10 families (86%) completed at least seven of the nine weeks in the program. Over the 16 week  
11  
12 follow-up, participants showed a reduction in the level of depressive symptoms (CDRS-R,  
13  
14  $d=1.17$ ) and externalizing symptoms (ADHD:  $d=0.30$ ; ODD:  $d=0.26$ ; CD:  $d=0.27$ ). Authors  
15  
16 interpreted the reduction in YMRS score ( $d=0.81$ ) as an improvement in mood lability among  
17  
18 participants.  
19  
20  
21  
22

23  
24 In an open-label uncontrolled study, Stoddard and colleagues examined the  
25  
26 preliminary efficacy of an intervention based on four sessions of computer-based Hostile  
27  
28 Interpretation Therapy [13]. The 14 included children (mean age  $14.1 \pm 2.4$  years) presented  
29  
30 DMDD. The gender ratio was 8:6 for female. DMDD symptoms were assessed using the  
31  
32 Affective Reactivity Index and the Clinical Global Impression- Improvement scale. Training  
33  
34 is designed to shift interpretation of ambiguous morphs bias toward happy judgments. Ten  
35  
36 subjects completed an implicit functional MRI face-emotion processing task. Active training  
37  
38 is associated with a shift in balance point toward more happy judgments (use as a proxy for  
39  
40 hostile attribution bias) ( $\beta = 2.25$  morphs). Evidence suggests that active training may be  
41  
42 associated with decreased irritability ( $\beta = -1.57$  in parent-report ARI score, no significant  
43  
44 change in self-report) and changes in activation patterns in the lateral orbitofrontal cortex.  
45  
46  
47  
48  
49  
50

### 51 52 53 3.1.2. Ongoing studies 54 55 56 57

58 Four trials were found searching the clinical trials registries that are underway.  
59  
60  
61  
62  
63  
64  
65

1 The group from Yale University started a randomized open-label controlled study in  
2 May 2013 to examine feasibility and preliminary efficacy of Dialectical Behaviour Therapy  
3 adapted to children (DBT-C) (NCT01862549). The study targets to include 60 7–12 year old  
4 children meeting DSM-5 criteria for DMDD. Participants are randomly assigned to receive  
5 one of two treatments for 30 weeks: DBT-C or enhanced care (active control condition).  
6  
7 Participants on the DBT-C arm received two pre-treatment sessions and 24 treatment sessions  
8 with once per week meetings, including 30 min individual child therapy, 20 min meeting with  
9 a caregiver and 40 min of skills training with both. Enhanced care consists of supportive  
10 individual psychotherapy, such as cognitive behavioural skills training and adjunctive family  
11 interventions (e.g., parenting skills training, structuring household environment, and safety  
12 planning). After the acute 32-week intervention period, 3-month follow-up assessments are  
13 conducted. The primary outcome is the attendance and drop-out rate measure, the level of  
14 satisfaction and compliance at 32 weeks; secondary end-points are reduction in DMDD  
15 symptoms and disruptive problems, psychosocial functioning and mental health service use.  
16  
17 Estimated primary completion date of the study is July 2015.

18  
19 The second ongoing study investigates the feasibility and acceptability of  
20 Interpersonal Psychotherapy for youths with SMD (IPT-SMD). A monocentric uncontrolled  
21 open-label study (NCT01591564) started in May 2012 and targeted to include five subjects  
22 who meet NIMH criteria for SMD. Youth receive weekly therapy sessions for 16 weeks and  
23 then bi-weekly sessions until week 20. Parent sessions are also included. The primary  
24 outcome is the retention rate and secondary end-points include various measures of clinical  
25 improvement. The investigators hypothesized that retention rates will be above 80% and the  
26 satisfaction score above six on a seven point scale. Although the results of this research have  
27 not yet been published, the same research team started a randomized rater-blind controlled  
28 study in October 2013 to test the effectiveness of Interpersonal Psychotherapy for Youth with  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Mood and Behaviour Dysregulation (IPT-MBD) on a more important sample size and allow  
2 for a longer follow-up time (NCT01962623). IPT-MBD is nearly identical to IPT-SMS,  
3  
4 except that bi-weekly sessions last until week 24. This study targets to include 44 youths  
5  
6 between 13 and 17 years meeting criteria for SMD. Primary and secondary outcomes are  
7  
8 similar to prior research. Estimated primary completion date of the study is August 2016.  
9

10  
11 A monocentric open-label uncontrolled study is underway since August 2015 to  
12  
13 compare the efficacy of CBT and Interpretation Bias Training (IBT) on DMDD  
14  
15 (NCT02531893). IBT is a newly developed computer-based training focusing on the socio-  
16  
17 emotional information process impairments described in youths with severe irritability (e.g.,  
18  
19 anger attribution bias). IBT is performed during 14 sessions over 10 weeks (four sessions in  
20  
21 four days, followed by eight weekly booster sessions after a two week delay) and CBT  
22  
23 consists of 12-16 weekly meetings. Primary outcomes are improvement in the Clinical Global  
24  
25 Impressions–Improvement score (CGI-I) and changes in irritability score using the Affective  
26  
27 Reactivity Index (ARI). A four-week wash-out period is planned for those who participate in  
28  
29 both treatments. Estimated primary completion date of the study is August 2019.  
30  
31  
32  
33  
34  
35

36 [Insert Table 1 about here]  
37  
38  
39  
40  
41

## 42 *3.2. Pharmacological treatments for DMDD*

### 43 *3.2.1. Completed studies*

44  
45  
46  
47 Only four completed pharmacological studies were eligible for the review (Table 1).  
48  
49

50  
51 In the secondary analysis of data from the 2003-2004 ADHD Summer Treatment  
52  
53 Program, Waxmonsky et al. examined the effectiveness of different doses of methylphenidate  
54  
55 (MPH) in SMD symptoms in children aged 5–12 with ADHD [36]. All subjects in each  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

psychotherapeutic group were treated with increasing MPH doses (placebo, 0.15 mg/kg, 0.3 mg/kg, and 0.6 mg/kg). As mentioned above, multimodal treatment produced a 34% reduction in YMRS ratings in SMD subjects.

Dickstein et al. led a placebo-controlled randomized trial to test the efficacy of lithium in SMD [24]. At admission 7–17 year old youths with SMD were tapered off previously prescribed medication. Those who continued to meet SMD criteria after a 2-week, single-blind, placebo run-in were randomized to a 6-week double-blind trial of either lithium (n=14) or placebo (n=11). The primary outcome measure was the CGI-I score less than four at trial's end. Magnetic resonance spectroscopy (MRS) was performed in all participants to measure biological markers known to be associated with lithium activity (i.e., myoinositol, N-acetyl-aspartate and combined glutamate). Almost half of the subjects (n=20) were not randomized due to significant clinical improvement during the placebo run-in. Among randomized patients, there were no significant between-group differences in either clinical or MRS outcome measures.

Krieger et al. conducted an open-label trial to determine the effectiveness of risperidone on youths with DMDD [40]. Of the 97 subjects initially assessed for severe irritability symptoms only 21 met DMDD criteria and were finally enrolled in the study. Evaluations were performed at baseline and weeks 2, 4, 6, and 8. The primary outcome measures were the Aberrant Behaviour Checklist–Irritability Subscale (ABC-Irritability) score, the CGI-I score and the severity of comorbid conditions. Risperidone was titrated from 0.5 to 3 mg/day in the first two weeks. A significant reduction of the ABC-Irritability score was observed after risperidone use. Authors reported a clinically significant improvement in ADHD and depression symptoms, as well as in global functioning.

Parmar et al. reported the case of a 15-year old boy presenting a DMDD and ADHD successfully treated with 50 mg of naltrexone [41]. Previous treatments received were



1 methylphenidate, guanfacine extended release, and aripiprazole at 5 mg to 15 mg once daily.  
2 Tolerability profile was good, except for an increased sedation. The lack of evidence  
3  
4 supporting long-term naltrexone justified the decision to stop the drug after three months.  
5  
6 Authors described a resurgence of patient's aggressive symptoms after drug discontinuation,  
7  
8 as well as an improvement after drug reintroduction.  
9  
10

### 14 3.2.2. Ongoing studies

16 Three pharmacological trials in SMD/DMDD youths are underway.

18  
19 Leibenluft et al. started in November 2008 a trial to determine the feasibility and  
20  
21 acceptability of MPH combined or not with citalopram, a selective serotonin re-uptake  
22  
23 inhibitor (SSRI) antidepressant, in youths with SMD (NCT00794040). A wash-out period is  
24  
25 followed by a 5-week dose stabilization phase of methylphenidate. Participants are then  
26  
27 randomly and blindly assigned to receive citalopram (target dose: 20-40 mg/day) or a placebo.  
28  
29 After eight weeks subjects were invited to participate in an open treatment phase for around  
30  
31 seven weeks. This study targets to include 160 7-17 year old youths who meet NIMH criteria  
32  
33 for SMD. The primary outcome measures are the ABC-Irritability score and the CGI-I score.  
34  
35 Estimated primary completion date of the study is October 2016.  
36  
37  
38  
39  
40

41 In January 2013, Mc Gough et al. started a preliminary study to evaluate the feasibility  
42  
43 and acceptability of lisdexamfetamine, a psychostimulant, combined or not with fluoxetine, a  
44  
45 SSRI antidepressant, in youths with SMD (NCT01714310). Participants have 4 weeks open  
46  
47 titration with lisdexamfetamine to optimal dose, followed by double-blind randomization  
48  
49 to fluoxetine or placebo in combination with optimized lisdexamfetamine for an additional  
50  
51 eight weeks. The investigators target to include 50 children aged 7–17 years old meeting  
52  
53 NIMH criteria for SMD (n=25, in each arm). The primary outcome is the Clinical Global  
54  
55 Impression-Improvement-Severe Mood Dysregulation, a categorical clinician rating of overall  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 improvement from baseline, modified by the NIMH to assess specific domains pertinent to  
2 SMD symptoms; secondary end-points are improvement in anxiety and mood symptoms,  
3  
4 emotion regulation and disruptive problems, changes on EEG profiles of cortical activity from  
5  
6 baseline at week 12. Estimated primary completion date of the study is July 2015.  
7  
8

9  
10         Gothelf et al. are conducting an ongoing trial since February 2014 in view of  
11  
12 comparing the feasibility and acceptability of MPH vs. risperidone in the treatment of youths  
13  
14 with both ADHD and DMDD (NCT02063945). Participants are randomly assigned to one of  
15  
16 the two arms. The primary outcome measure is the reduction of aggressive behaviour  
17  
18 (measured with the Retrospective Modified Overt Aggression Scale) after an 8-week  
19  
20 treatment. This study targets to include 70 youths (5-18 year old) who meet DSM-5 criteria  
21  
22 for both DMDD and ADHD. Estimated primary completion date of the study is February  
23  
24 2016.  
25  
26  
27

28  
29                                 [Insert Table 2, about here]  
30

31  
32                                 [Insert Table 3, about here]  
33  
34  
35  
36  
37  
38  
39  
40

#### 41         **4. DISCUSSION** 42

##### 43 44 45 46         *4.1. Treatment efficacy and tolerability* 47 48

49  
50  
51         At present there is only very limited empirical evidence for interventions in SMD or  
52  
53 DMDD youths. Behaviour therapy or CBT associated with parental training showed a  
54  
55 potential for symptom reduction and improvement of global functioning among youths with  
56  
57 both ADHD and SMD [36,37]. This is in line with the efficacy of parental guidance  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
previously reported in youths with ADHD and behaviour problems [42]. In one study, the  
analyses were performed post-hoc in a subsample of the overall randomized group [36], thus  
calling successful randomization into question. In the second analysis, the small sizes of the  
sample make it difficult to prevent from generalizing to other population [37]. One pilot study  
shows encouraging results for the possible benefit of Interpretation Bias Therapy [13]. The  
rationale for the development of IBT in DMDD (also evaluated in NCT02531893) is based on  
the difficulties in performing specific cognitive tasks reported in this population (e.g.,  
attentional bias to threat, poor inhibitory control) [20]. Four controlled studies are currently  
under way to test the effects of psychotherapeutic interventions. The benefit of DBT or IPT in  
DMDD (evaluated in NCT01862549, NCT01591564, NCT01962623) is hypothesised from  
available evidence for positive effects in youths with other internalizing disorders [43-46].  
DBT, historically developed for chronically suicidal adults with borderline personality  
disorder, was regarded as effective to target mood dysregulation across a range of diagnoses  
[44]. Empirical studies support the use of DBT with adolescents diagnosed with depression  
[44], bipolar disorder [45] and ODD [47]. IPT is a brief psychotherapy successfully developed  
to target depressive symptoms in adolescents [46]. In addition to the patient's mood  
symptoms, focus is placed on the interpersonal context in which they occur. The greater  
emphasis of IPT on basic social skills and on learning to negotiate relationally could be  
particularly relevant to address emotional reactivity and poor tolerance to frustration in  
DMDD youths.

48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
Concerning a pharmacological approach, four studies were identified [36,24,40,41].  
Lithium carbonate was not found to be more effective than placebo in young inpatients with  
SMD [24]. However, preliminary results support a positive effect of risperidone for  
decreasing irritability and externalized symptoms in SMD youths [40]. A possible effect of  
naltrexone (one single case only) is reported in a 15-year old boy with ADHD and DMDD

1 [41]. Psychostimulant was found partly effective on youths with ADHD and SMD to treat  
2 SMD symptoms [36]. This finding is consistent with meta-analyses demonstrating an efficacy  
3 of psychostimulant on irritability [48] and in reactive aggression [49] in ADHD youths.  
4  
5 However, in line with a prior study [32], Waxmonsky et al. [36] noted that psychostimulant  
6 remains only partially effective in this patient. In the ADHD-STP study, only 6% of youths  
7 with ADHD and SMD were in remission at endpoint, compared to 27% in the control group  
8 (ADHD without SMD) [36]. Such findings build a rationale for the development of “add-on”  
9 pharmacological strategy; i.e., the use of a second line of medication (different from  
10 psychostimulant) in youths with both ADHD and SMD/DMDD criteria. Currently, two  
11 controlled studies are under way to further clarify whether adding an SSRI antidepressant can  
12 decrease DMDD symptomatology (NCT00794040, NCT01714310). Following another  
13 pharmacological approach, one study tests the comparative efficacy of an atypical  
14 antipsychotic and a psychostimulant as a first line treatment in youths with ADHD and  
15 DMDD (NCT02063945). In particular, risperidone seems to be a promising molecule ([40],  
16 NCT02063945) in regards to its uses in the treatment of severe irritability in youths with other  
17 psychiatric disorders (e.g., autism spectrum disorder or intellectual disability) [4]. Of note, no  
18 study was conducted to test the possible benefit of selective norepinephrine reuptake  
19 inhibitors, mood stabilizers, or alpha-2 agonists, despite preliminary studies showing a  
20 possible benefit of these medications for youths with severe irritability [4].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 *4.2.Limitations*

49  
50  
51  
52  
53 Several methodological weaknesses of the studies available for review may be partly  
54 responsible for the limited knowledge available in this field. We identified three sources that  
55 presented level II-1 evidence, one for level II-2 evidence, and three for level II-3 evidence. No  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 source for level I evidence study was found. In the next paragraphs we discuss the principal  
2 limitation of these studies and suggest possible improvements.  
3  
4  
5

#### 6 7 4.2.1. Eligibility criteria 8

9 Criteria for DMDD have only been defined since May 2013, i.e. the publishing of the  
10 DSM-5 [6], whereas NIMH criteria for SMD have been operationalized since 2001 [34].  
11  
12 Consequently, the participant eligibility was based on SMD criteria in most of the reviewed  
13 studies. Results of published studies focusing on SMD youths should not be extrapolated to  
14 youths with DMDD without caution, as the two constructs are not similar. As the  
15 “hyperarousal” criterion exists for SMD but not for DMDD, treatments that are effective in  
16 decreasing hyperarousal symptoms (e.g., benzodiazepines) may be mistakenly regarded as  
17 effective for DMDD. As the profile of comorbid psychiatric disorders of SMD and DMDD  
18 can differ slightly [10] the impact of specific treatments (e.g., psychostimulant) on DMDD  
19 could be under- or overestimated if data are extrapolated from studies conducted in SMD  
20 youths. We suggest that only the DMDD category should be used in future research, and if  
21 not, detailed analysis of treatment response for each symptom should be provided.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 The rate of comorbidity between DMDD and externalizing disorders was high in all  
40 studies and especially between DMDD and ADHD (ranging from 71% to 100%) [24,41,40].  
41  
42 As diagnostic criteria overlap between these two disorders, studies conducted in youths with  
43 both ADHD and DMDD should examine whether the improvement in DMDD symptoms is  
44 not due to the impact of the treatment on shared symptoms. Waxmonsky et al. noted that 23%  
45 of the total severity score change occurred in items overlapping with ADHD symptoms [36].  
46  
47 Again, item-by-item analysis that was not performed in other studies could be useful.  
48  
49  
50  
51  
52  
53  
54

55 This review highlights the importance of using both a measure of general  
56 improvement, such as the CGI-I, and a specific measure for symptoms severity. There are two  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 reasons why the scales used to measure the main outcomes may be inappropriate. First, some  
2 of them were developed for manic symptoms (e.g., the YMRS) [36,37]; therefore, a decrease  
3  
4 in total score may reflect a reduction in items such as loss of appetite or sleep changes which  
5  
6 are not associated with DMDD. Second, other authors used subscores of scales that were not  
7  
8 originally developed for irritability (e.g., the ABC—Irritability or the PANSS subscore)  
9  
10 [24,40]. Content validity of such subscales is problematic as it may not cover all aspects of  
11  
12 DMDD leading to biased results, while their poor reliability increases the risk of erroneous  
13  
14 conclusion [50]. Moreover, as noted by Leibenluft, irritability, aggressive behaviors and  
15  
16 hostility are embedded by distinct, even if somewhat related, pathophysiological process [51];  
17  
18 they therefore should be regarded as different therapeutic targets. At best, authors should use  
19  
20 scales specifically developed to measure irritability and temper outburst such as the Affective  
21  
22 Reactivity Index [52] or the Child Affective Lability Scale [53].  
23  
24  
25  
26  
27  
28

29 Exclusion criteria regarding intellectual disability, autism spectrum disorder and  
30  
31 distinct manic episode were respected in line with NIMH and APA recommendations [5,6].  
32  
33 Of note, some studies included subjects with suicidal ideations (NCT01862549), whereas  
34  
35 others did not (NCT01591564, NCT01962623). The status of medication was discussed in all  
36  
37 except one study (NCT02531893). Authors recommend that psychotropic medication should  
38  
39 not be used in a time period ranging from four weeks (NCT01591564) to six months [40]. At  
40  
41 best, a period of medication withdrawal should be conducted after the period of inclusion  
42  
43 (NCT00794040, [40]).  
44  
45  
46  
47  
48  
49

#### 50 4.2.2. Design

51 A high level of placebo response was observed in the only placebo-controlled study  
52  
53 [24]. This finding is consistent with the substantial decline in symptomatology scores  
54  
55 experienced by the placebo group in RCT-DB of adolescents with mood disorders, such as  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 mania [54,55] or depressive disorder [56,57]. It has been noted that most of the placebo effect  
2 in antidepressant trials occurs during the first two weeks of treatment [58], possibly due to the  
3  
4 therapeutic effects of meeting with health professionals [56]. Interestingly, Krieger et al.  
5  
6 observed a slight increase in the level of symptomatology at four weeks compared to it at two  
7  
8 weeks of treatment [40]. It could be somewhat comparable to the “honey moon” observed in  
9  
10 SMD young patients who exhibited significant improvement in symptoms after admission  
11  
12 that have not persisted with time [36], or the rapid improvement in non-medicated youths  
13  
14 admitted to hospitalization for severe rage episodes [14]. On the one hand, we suggest that  
15  
16 authors examine how DMDD-symptom scores change gradually over the trial to make sure  
17  
18 than the decline does not occur only at the very beginning of the treatment after the inclusion.  
19  
20  
21 On the other hand, a run-in period before randomization may be useful to distinguish a “real”  
22  
23 pharmacological effect from the positive impact of non-specific interventions (e.g., supportive  
24  
25 psychotherapy, cares provided by a structured milieu, or the removal from a stressful  
26  
27 environment) [56,57], in particular when the subject is randomized just after admission in a  
28  
29 psychiatric ward.  
30  
31  
32  
33  
34  
35  
36  
37  
38

#### 39 4.2.3. Measures of tolerability and acceptance

40  
41 Tolerability and acceptance were systematically measured with specific scales in all  
42  
43 pharmacological studies. Considering the fact that irritability is both a symptom of DMDD  
44  
45 and a possible side effect of many psychotropic medications, especially SSRI [59] and  
46  
47 stimulant [60], it may be useful to determine whether a dose-effect relationships occurs  
48  
49 between the treatment dose or duration and the severity of side effects (as shown in [40]).  
50  
51  
52 Paraclinical examinations were adequately performed to examine possible metabolic side  
53  
54 effects of atypical antipsychotic agents [40], or the effect of lithium carbonate on thyroid  
55  
56 function [24].  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 *4.3. Clinical and research implications*  
4  
5  
6  
7

8 In this research we reviewed the evidence for supporting the clinical benefits of  
9  
10 psychotherapeutic and pharmacological treatments for DMDD/SMD youths. Further research  
11  
12 would help to clarify the mechanisms involved at different levels (psychological, cognitive or  
13  
14 relational). As discussed in the introduction, we thought that complementary approaches are  
15  
16 also needed, in particular exploring the positive impact of such treatments on a clinical  
17  
18 construct such as a youth's emotional dysregulation while adopting a trans-nosological view.  
19  
20 Severe emotional dysregulation is a key characteristic of SMD/DMDD, but it is also seen as a  
21  
22 core symptom for other DSM-5 disorders such as trauma-related disorders (e.g., complex  
23  
24 PTSD, reactive attachment disorder), borderline personality disorder (BPD), or intermittent  
25  
26 explosive disorders in DSM-5.  
27  
28  
29  
30  
31

32  
33 Future research should reveal whether, and to what extent, the severely dysregulated  
34  
35 prepubertal youths presenting SMD/DMDD criteria develop other psychiatric disorders in  
36  
37 adolescence (especially borderline personality disorder). In turn, findings from clinical trials  
38  
39 conducted in youths with mood dysregulation-related disorders can inform future projects for  
40  
41 SMD/DMDD therapeutic studies. For example, antipsychotics that have shown beneficial  
42  
43 effects in the short-term on cognitive-perceptual symptoms, anger, and mood lability in those  
44  
45 with BPD [61] have not demonstrated effectiveness for longer use. Interestingly,  
46  
47 psychotherapies that focus on the development of secure bounds and relational difficulties  
48  
49 (e.g., Dialectical Behavioral Therapy or Mentalizing-Based Therapy) exhibit the highest level  
50  
51 of evidence for youths with BPD features [62]. The interplay between the development of  
52  
53 emotional and social abilities throughout childhood, as stressed in various theoretical models  
54  
55 (e.g., the socio-emotional developmental model, the psychodynamic view of object relations  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 theory, or the attachment theory), highlights the possible benefit of promoting the youths'  
2 social skills while caring for mood dysregulation. Surprisingly no study was devoted to the  
3 impact of family interventions in SMD/DMDD youths. The importance of parent-child  
4 quality of interactions on the emergence of child's emotion regulation strategies has however  
5 been supported in epidemiological and clinical studies (for a review [63]). Moreover, the  
6 bidirectional relationships between a child's degree of emotional distress and the parental  
7 level of adjustment has been regarded as a key mechanism to understand the persistence of  
8 symptoms [16].  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

#### 23 *4.4. Conclusion*

24  
25  
26  
27  
28 The two current pharmacological strategies tested for SMD and DMDD patients are a  
29 monotherapy of psychostimulants or atypical antipsychotics and the use of SSRI as an add-on  
30 therapy in youths with comorbid ADHD and treated with psychostimulant. Psychotherapeutic  
31 treatments currently being tested are based on methods previously developed for depression  
32 (e.g., IPT, DBT) and/or youths with ADHD and behavioural problems (e.g., parental  
33 behavioural guidance). The overall level of available evidence remains dramatically poor  
34 regarding clinical needs, in particular with regards to the size of the sample studied and the  
35 heterogeneity of inclusion criteria. Moreover, the lack of follow-up above 8 weeks prevents  
36 current studies from being conclusive for the impact of treatment over a short-term duration.  
37  
38 Future studies will further clarify the effectiveness of therapeutic interventions for DMDD  
39 individuals. Such studies should (i) be conducted in large multi-site studies, (ii) with specific  
40 and standardized procedures to measure DMDD symptom improvements, and (iii) include a  
41 run-in period to limit placebo effect.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**LIST OF ABBREVIATIONS USED:** Disruptive Mood Dysregulation Disorder (DMDD); Severe Mood Dysregulation (SMD); Attention Deficit with Hyperactivity Disorder (ADHD); Oppositional Defiant Disorder (ODD); Conduct Disorder (CD); Separation Anxiety Disorder (SAD); Anxiety Disorders (AD); Major Depressive Disorder (MDD); National Institute of Mental Health (NIMH); Cognitive Behavioral Therapy (CBT); Behavioral Parental Training (BPT); Disruptive Behavior Disorders Interview (DBD); Washington University Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS); Clinical Global Impressions–Improvement (CGI-I); Clinical Global Impressions–Severity (CGI-S)

## REFERENCES

1. Masi G, Pisano S, Milone A, Muratori P (2015) Child behavior checklist dysregulation profile in children with disruptive behavior disorders: A longitudinal study. *J Affect Disord* 186:249-253. doi:10.1016/j.jad.2015.05.069
2. Roy AK, Lopes V, Klein RG (2014) Disruptive Mood Dysregulation Disorder: A New Diagnostic Approach to Chronic Irritability in Youth. *American Journal of Psychiatry* 171 (9):918-924. doi:doi:10.1176/appi.ajp.2014.13101301
3. Consoli A, Cohen D (2013) Manic-like symptoms in youths: Diagnosis issues and controversies. *Neuropsychiatrie de l'Enfance et de l'Adolescence* 61:154-159
4. Tourian L, LeBoeuf A, Breton JJ, Cohen D, Gignac M, Labelle R, Guile JM, Renaud J (2015) Treatment Options for the Cardinal Symptoms of Disruptive Mood Dysregulation Disorder. *J Can Acad Child Adolesc Psychiatry* 24 (1):41-54
5. Leibenluft E, Blair RJ, Charney DS, Pine DS (2003) Irritability in pediatric mania and other childhood psychopathology. *Ann N Y Acad Sci* 1008:201-218
6. American Psychiatric Association (2013) *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition*. American Psychiatric Association,
7. Dougherty LR, Smith VC, Bufferd SJ, Carlson GA, Stringaris A, Leibenluft E, Klein DN (2014) DSM-5 disruptive mood dysregulation disorder: correlates and predictors in young children. *Psychol Med* 44 (11):2339-2350. doi:10.1017/S0033291713003115
8. Copeland WE, Angold A, Costello EJ, Egger H (2013) Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder. *Am J Psychiatry* 170 (2):173-179. doi:10.1176/appi.ajp.2012.12010132
9. Copeland WE, Shanahan L, Egger H, Angold A, Costello EJ (2014) Adult diagnostic and functional outcomes of DSM-5 disruptive mood dysregulation disorder. *Am J Psychiatry* 171 (6):668-674. doi:10.1176/appi.ajp.2014.13091213
10. Axelson D, Findling RL, Fristad MA, Kowatch RA, Youngstrom EA, Horwitz SM, Arnold LE, Frazier TW, Ryan N, Demeter C, Gill MK, Hauser-Harrington JC, Depew J, Kennedy SM, Gron BA, Rowles BM, Birmaher B (2012) Examining the proposed disruptive mood dysregulation disorder diagnosis in children in the Longitudinal Assessment of Manic Symptoms study. *J Clin Psychiatry* 73 (10):1342-1350. doi:10.4088/JCP.12m07674
11. Margulies DM, Weintraub S, Basile J, Grover PJ, Carlson GA (2012) Will disruptive mood dysregulation disorder reduce false diagnosis of bipolar disorder in children? *Bipolar Disord* 14 (5):488-496. doi:10.1111/j.1399-5618.2012.01029.x

12. Lochman JE, Evans SC, Burke JD, Roberts MC, Fite PJ, Reed GM, de la Pena FR, Matthys W, Ezpeleta L, Siddiqui S, Elena Garralda M (2015) An empirically based alternative to DSM-5's disruptive mood dysregulation disorder for ICD-11. *World Psychiatry* 14 (1):30-33. doi:10.1002/wps.20176
13. Stoddard J, Sharif-Askary B, Harkins EA, Frank HR, Brotman MA, Penton-Voak IS, Maoz K, Bar-Haim Y, Munafo M, Pine DS, Leibenluft E (2016) An Open Pilot Study of Training Hostile Interpretation Bias to Treat Disruptive Mood Dysregulation Disorder. *J Child Adolesc Psychopharmacol* 26 (1):49-57. doi:10.1089/cap.2015.0100
14. Carlson GA, Potegal M, Margulies D, Gutkovich Z, Basile J (2009) Rages--what are they and who has them? *J Child Adolesc Psychopharmacol* 19 (3):281-288. doi:10.1089/cap.2008.0108
15. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M (2007) National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. *Arch Gen Psychiatry* 64 (9):1032-1039. doi:10.1001/archpsyc.64.9.1032
16. Stringaris A, Taylor E (2015) Disruptive Mood: Irritability in Children and Adolescent.
17. Brotman MA, Schmajuk M, Rich BA, Dickstein DP, Guyer AE, Costello EJ, Egger HL, Angold A, Pine DS, Leibenluft E (2006) Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. *Biol Psychiatry* 60 (9):991-997. doi:10.1016/j.biopsych.2006.08.042
18. Stringaris A, Baroni A, Haimm C, Brotman M, Lowe CH, Myers F, Rustgi E, Wheeler W, Kayser R, Towbin K, Leibenluft E (2010) Pediatric bipolar disorder versus severe mood dysregulation: risk for manic episodes on follow-up. *J Am Acad Child Adolesc Psychiatry* 49 (4):397-405
19. Brotman MA, Kassem L, Reising MM, Guyer AE, Dickstein DP, Rich BA, Towbin KE, Pine DS, McMahon FJ, Leibenluft E (2007) Parental diagnoses in youth with narrow phenotype bipolar disorder or severe mood dysregulation. *Am J Psychiatry* 164 (8):1238-1241. doi:10.1176/appi.ajp.2007.06101619
20. Guyer AE, McClure EB, Adler AD, Brotman MA, Rich BA, Kimes AS, Pine DS, Ernst M, Leibenluft E (2007) Specificity of facial expression labeling deficits in childhood psychopathology. *J Child Psychol Psychiatry* 48 (9):863-871. doi:10.1111/j.1469-7610.2007.01758.x
21. Rich BA, Carver FW, Holroyd T, Rosen HR, Mendoza JK, Cornwell BR, Fox NA, Pine DS, Coppola R, Leibenluft E (2011) Different neural pathways to negative affect in youth with pediatric bipolar disorder and severe mood dysregulation. *J Psychiatr Res* 45 (10):1283-1294. doi:10.1016/j.jpsychires.2011.04.006
22. Dickstein DP, Gorrostieta C, Ombao H, Goldberg LD, Brazel AC, Gable CJ, Kelly C, Gee DG, Zuo X-N, Castellanos FX, Milham MP (2010) Fronto-Temporal Spontaneous Resting State Functional Connectivity in Pediatric Bipolar Disorder. *Biological Psychiatry* 68 (9):839-846. doi:<http://dx.doi.org/10.1016/j.biopsych.2010.06.029>
23. Brotman MA, Rich BA, Guyer AE, Lunsford JR, Horsey SE, Reising MM, Thomas LA, Fromm SJ, Towbin K, Pine DS, Leibenluft E (2010) Amygdala activation during emotion processing of neutral faces in children with severe mood dysregulation versus ADHD or bipolar disorder. *Am J Psychiatry* 167 (1):61-69. doi:10.1176/appi.ajp.2009.09010043
24. Dickstein DP, Towbin KE, Van Der Veen JW, Rich BA, Brotman MA, Knopf L, Onelio L, Pine DS, Leibenluft E (2009) Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. *J Child Adolesc Psychopharmacol* 19 (1):61-73. doi:10.1089/cap.2008.044
25. Comer JS, Olfson M, Mojtabai R (2010) National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. *J Am Acad Child Adolesc Psychiatry* 49 (10):1001-1010. doi:10.1016/j.jaac.2010.07.007
26. Olfson M, Crystal S, Huang C, Gerhard T (2010) Trends in antipsychotic drug use by very young, privately insured children. *J Am Acad Child Adolesc Psychiatry* 49 (1):13-23
27. Parens E, Johnston J, Carlson GA (2010) Pediatric mental health care dysfunction disorder? *The New England journal of medicine* 362 (20):1853-1855. doi:10.1056/NEJMp1003175
28. Sparks GM, Axelson DA, Yu H, Ha W, Ballester J, Diler RS, Goldstein B, Goldstein T, Hickey MB, Ladouceur CD, Monk K, Sakolsky D, Birmaher B (2014) Disruptive mood dysregulation

disorder and chronic irritability in youth at familial risk for bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 53 (4):408-416. doi:10.1016/j.jaac.2013.12.026

29. Efron D, Sciberras E, Anderson V, Hazell P, Ukoumunne OC, Jongeling B, Schilpzand EJ, Bisset M, Nicholson JM (2014) Functional status in children with ADHD at age 6-8: a controlled community study. *Pediatrics* 134 (4):e992-e1000. doi:10.1542/peds.2014-1027

30. Mulraney M, Schilpzand EJ, Hazell P, Nicholson JM, Anderson V, Efron D, Silk TJ, Sciberras E (2015) Comorbidity and correlates of disruptive mood dysregulation disorder in 6-8-year-old children with ADHD. *Eur Child Adolesc Psychiatry*. doi:10.1007/s00787-015-0738-9

31. Fernandez de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A (2015) Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA). *J Am Acad Child Adolesc Psychiatry* 54 (1):62-70.e63. doi:10.1016/j.jaac.2014.10.006

32. Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, Chuang SZ, Elliott GR, Arnold LE, March JS, Hechtman L, Pelham WE, Swanson JM (2003) Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. *J Child Adolesc Psychopharmacol* 13 (2):123-136. doi:10.1089/104454603322163844

33. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 339:b2535. doi:10.1136/bmj.b2535

34. Leibenluft E (2011) Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths. *American Journal of Psychiatry* 168:129-142. doi:10.1176/appi.ajp.2010.10050766

35. US Preventive Services Task Force (1996) Guide to clinical preventive services. In: Quality AfHRa (ed). Washington (DC),

36. Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O'Connor B, Majumdar A, Verley J, Hoffman MT, Massetti GA, Burrows-MacLean L, Fabiano GA, Waschbusch DA, Chacko A, Arnold FW, Walker KS, Garefino AC, Robb JA (2008) The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. *J Child Adolesc Psychopharmacol* 18 (6):573-588. doi:10.1089/cap.2008.065

37. Waxmonsky JG, Wymbs FA, Pariseau ME, Belin PJ, Waschbusch DA, Babocsai L, Fabiano GA, Akinnusi OO, Haak JL, Pelham WE (2013) A novel group therapy for children with ADHD and severe mood dysregulation. *Journal of attention disorders* 17 (6):527-541. doi:10.1177/1087054711433423

38. Fabiano GA, Pelham WE, Gnagy EM, Burrows-MacLean L, Coles EK, Chacko A, Wymbs BT, Walker KS, Arnold F, Garefino A, Keenan JK, Onyango AN, Hoffman MT, Massetti GM, Robb JA (2007) The single and combined effects of multiple intensities of behavior modification and methylphenidate for children with attention deficit hyperactivity disorder in a classroom setting. *School Psychol Rev* 36 (2):195-216

39. Pelham WE, Greiner A, Gnagy EM (1997) Children's Summer Treatment Program Manual. In: Inc (ed) *Comprehensive Treatment for Attention Disorders*. Buffalo, NY,

40. Krieger FV, Pheula GF, Coelho R, Zeni T, Tramontina S, Zeni CP, Rohde LA (2011) An open-label trial of risperidone in children and adolescents with severe mood dysregulation. *J Child Adolesc Psychopharmacol* 21 (3):237-243. doi:10.1089/cap.2010.0123

41. Parmar A, Vats D, Parmar R, Aligeti M (2014) Role of naltrexone in management of behavioral outbursts in an adolescent male diagnosed with disruptive mood dysregulation disorder. *J Child Adolesc Psychopharmacol* 24 (10):594-595. doi:10.1089/cap.2014.0072

42. Périssé D, Gerardin P, Cohen D, Flament M, Mazet P (2006) Conduct disorder in children and adolescents: a review of current therapeutic approaches. *Neuropsychiatrie de l'enfance et de l'adolescence* 54:401-410. doi:10.1016/j.neurenf.2005.09.006

43. Zhou X, Hetrick SE, Cuijpers P, Qin B, Barth J, Whittington CJ, Cohen D, Del Giovane C, Liu Y, Michael KD, Zhang Y, Weisz JR, Xie P (2015) Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta-analysis. *World Psychiatry* 14 (2):207-222. doi:10.1002/wps.20217

- 1 44. MacPherson HA, Cheavens JS, Fristad MA (2013) Dialectical behavior therapy for  
adolescents: theory, treatment adaptations, and empirical outcomes. *Clinical child and*  
2 *family psychology review* 16 (1):59-80. doi:10.1007/s10567-012-0126-7
- 3 45. Goldstein TR, Fersch-Podrat RK, Rivera M, Axelson DA, Merranko J, Yu H, Brent DA, Birmaher  
4 B (2015) Dialectical behavior therapy for adolescents with bipolar disorder: results from a pilot  
5 randomized trial. *J Child Adolesc Psychopharmacol* 25 (2):140-149. doi:10.1089/cap.2013.0145
- 6 46. Mufson L, Sills R (2006) Interpersonal Psychotherapy for depressed adolescents (IPT-A): an  
7 overview. *Nordic journal of psychiatry* 60 (6):431-437. doi:10.1080/08039480601022397
- 8 47. Nelson-Gray RO, Keane SP, Hurst RM, Mitchell JT, Warburton JB, Chok JT, Cobb AR (2006) A  
9 modified DBT skills training program for oppositional defiant adolescents: promising  
10 preliminary findings. *Behav Res Ther* 44 (12):1811-1820. doi:10.1016/j.brat.2006.01.004
- 11 48. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH, Jr. (2002) Psychopharmacology and  
12 aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related  
13 behaviors in ADHD. *J Am Acad Child Adolesc Psychiatry* 41 (3):253-261. doi:10.1097/00004583-  
14 200203000-00004
- 15 49. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS (2006)  
16 Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. *J Can*  
17 *Acad Child Adolesc Psychiatry* 15 (1):27-39
- 18 50. Rust J, Golombok S (2009) *Modern Psychometrics. The science of psychological*  
19 *assessment*. 3 edn., London and New York
- 20 51. Leibenluft E, Stoddard J (2013) The developmental psychopathology of irritability. *Dev*  
21 *Psychopathol* 25 (4 Pt 2):1473-1487. doi:10.1017/s0954579413000722
- 22 52. Stringaris A, Goodman R, Ferdinando S, Razdan V, Muhrer E, Leibenluft E, Brotman MA  
23 (2012) The Affective Reactivity Index: a concise irritability scale for clinical and research  
24 settings. *J Child Psychol Psychiatry* 53 (11):1109-1117. doi:10.1111/j.1469-7610.2012.02561.x
- 25 53. Guile JM, Chapdelaine C, Desrosiers L, Cornez C, Bouvier H, Breton JJ (2009) Preliminary  
26 reliability study of the affective lability scale adapted for adolescents in a francophone  
27 clinical population. *J Can Acad Child Adolesc Psychiatry* 18 (4):293-306
- 28 54. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, D'Souza J, Wamil  
29 A, Lehman RB, Berv D, Linden D (2006) A double-blind, randomized, placebo-controlled trial  
30 of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. *Am J*  
31 *Psychiatry* 163 (7):1179-1186. doi:10.1176/ajp.2006.163.7.1179
- 32 55. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K,  
33 Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J (2007) Olanzapine  
34 versus placebo in the treatment of adolescents with bipolar mania. *Am J Psychiatry* 164  
35 (10):1547-1556. doi:10.1176/appi.ajp.2007.06111932
- 36 56. Cohen D, Consoli A, Bodeau N, Purper-Ouakil D, Deniau E, Guile JM, Donnelly C (2010)  
37 Predictors of placebo response in randomized controlled trials of psychotropic drugs for  
38 children and adolescents with internalizing disorders. *J Child Adolesc Psychopharmacol* 20  
39 (1):39-47. doi:10.1089/cap.2009.0047
- 40 57. Cohen D, Deniau E, Maturana A, Tanguy ML, Bodeau N, Labelle R, Breton JJ, Guile JM  
41 (2008) Are child and adolescent responses to placebo higher in major depression than in  
42 anxiety disorders? A systematic review of placebo-controlled trials. *PLoS one* 3 (7):e2632.  
43 doi:10.1371/journal.pone.0002632
- 44 58. Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP (2011)  
45 Deconstructing pediatric depression trials: an analysis of the effects of expectancy and  
46 therapeutic contact. *J Am Acad Child Adolesc Psychiatry* 50 (8):782-795.  
47 doi:10.1016/j.jaac.2011.04.004
- 48 59. Henry A, Kisicki MD, Varley C (2012) Efficacy and safety of antidepressant drug treatment  
49 in children and adolescents. *Mol Psychiatry* 17 (12):1186-1193. doi:10.1038/mp.2011.150
- 50 60. Efron D, Jarman F, Barker M (1997) Side effects of methylphenidate and dexamphetamine  
51 in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.  
52 *Pediatrics* 100 (4):662-666
- 53 61. Ingenhoven TJ, Duivenvoorden HJ (2011) Differential effectiveness of antipsychotics in  
54 borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical  
55 trials on symptomatic outcome domains. *Journal of clinical psychopharmacology* 31 (4):489-  
56 496. doi:10.1097/JCP.0b013e3182217a69
- 57  
58  
59  
60  
61  
62  
63  
64  
65

62. Fonagy P, Speranza M, Luyten P, Kaess M, Hessels C, Bohus M (2015) ESCAP Expert Article: borderline personality disorder in adolescence: an expert research review with implications for clinical practice. *Eur Child Adolesc Psychiatry* 24 (11):1307-1320. doi:10.1007/s00787-015-0751-z

63. Dvir Y, Ford JD, Hill M, Frazier JA (2014) Childhood maltreatment, emotional dysregulation, and psychiatric comorbidities. *Harvard review of psychiatry* 22 (3):149-161. doi:10.1097/HRP.000000000000014

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



[Click here to view linked References](#)

1  
2  
3 Evidence-based treatments for youths with severely dysregulated  
4  
5  
6 mood: a qualitative systematic review of trials for SMD and DMDD  
7  
8  
9

10  
11  
12 Xavier Benarous<sup>1</sup> [xavierbenarous@gmail.com](mailto:xavierbenarous@gmail.com), Angèle Consoli<sup>1,2</sup> [angele.consoli@psl.aphp.fr](mailto:angele.consoli@psl.aphp.fr), Jean-Marc Guilé<sup>1,3,4</sup>  
13 [guile.jean-marc@chu-amiens.fr](mailto:guile.jean-marc@chu-amiens.fr), Sébastien Garny de La Rivière<sup>3</sup> [garnydelariviere.sebastien@chu-amiens.fr](mailto:garnydelariviere.sebastien@chu-amiens.fr),  
14  
15 David Cohen<sup>1,5</sup> [david.cohen@psl.aphp.fr](mailto:david.cohen@psl.aphp.fr), Bertrand Olliac<sup>1,6</sup> [bertrand.olliac@gmail.com](mailto:bertrand.olliac@gmail.com)  
16  
17  
18

19  
20 <sup>1</sup> Department of Child And Adolescent Psychiatry, Pitié-Salpêtrière Hospital, 47-83 boulevard de l'Hôpital, 75013  
21 Paris, France

22  
23 <sup>2</sup> INSERM U-669, PSIGIAM, Paris, France

24  
25 <sup>3</sup> Groupe de Recherches sur l'Analyse Multimodale de la Fonction Cérébrale, INSERM U1105, CHU, Université  
26 Picardie Jules Verne, Amiens, France

27  
28 <sup>4</sup> Department of Psychiatry, McGill University, Montreal, Canada

29  
30 <sup>5</sup> CNRS UMR 7222, Institute for Intelligent Systems and Robotics-ISIR, Paris, France

31  
32 <sup>6</sup> Pôle Hospitalo-Universitaire de psychiatrie de l'enfant et de l'adolescent, Centre Hospitalier Esquirol, Limoges,  
33 France  
34  
35  
36

37  
38 **Address of correspondence:** Xavier Benarous, Department of Child And Adolescent Psychiatry, Pitié-Salpêtrière  
39 Hospital, 47-83 boulevard de l'Hôpital, 75013 Paris, France

40  
41 **Email:** [xavierbenarous@gmail.com](mailto:xavierbenarous@gmail.com)

42  
43 **Phone:** +33(0)603260193

44  
45 **Fax:** +33(0)142162331

46  
47 **Category:** Review article

48  
49 **Abbreviated title:** Treatments for youths with SMD and DMDD

50  
51 **Conflict of interest:** On behalf of all authors, the corresponding author states that there is no conflict of interest.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## ABSTRACT

1  
2  
3 The aim of this literature review was to examine the evidence for psychotherapeutic and  
4 pharmacological treatments in subjects with severely dysregulated mood and to identify  
5 potential areas for improvements in research designs. A literature search was conducted using  
6 several databases for published (PubMed, PsycINFO) and ongoing (clinical trial registries)  
7 studies conducted in youths who met NIMH's criteria for Severe Mood Dysregulation (SMD)  
8 or the DSM-5 diagnosis of Disruptive Mood Dysregulation Disorder (DMDD). Eight  
9 completed studies were identified: three randomized trials, four open pilot studies and one  
10 case report. Seven ongoing studies were found in trial registries. The available evidence  
11 suggests potential efficacy of psychotherapies which have previously been developed for  
12 internalizing and externalizing disorders. The two main pharmacological strategies tested are,  
13 first, a monotherapy of psychostimulant or atypical antipsychotic such as risperidone, already  
14 used in the treatment of severe irritability in youths with developmental disorders; and  
15 second, the use of a serotonergic antidepressant as an add-on therapy in youths treated with  
16 psychostimulant. Ongoing studies will further clarify the effectiveness of psychotherapeutic  
17 interventions for DMDD individuals and whether they should be given alone or in  
18 conjunction with other treatments. The short duration of the trials for a chronic disorder, the  
19 low number of studies, the lack of placebo or active comparator arm, and restrictive inclusion  
20 criteria in most of the controlled trials dramatically limit the interpretation of the results.  
21 Finally, future research should be conducted across multiple sites, with standardized  
22 procedures to measure DMDD symptoms reduction, and include a run-in period to limit  
23 placebo effect.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54  
55  
56  
57  
58 **KEYWORDS:** disruptive mood dysregulation disorder; severe mood dysregulation;  
59 psychotherapy; pharmacotherapy; therapeutics; irritability  
60  
61  
62  
63  
64  
65



# 1. INTRODUCTION

## 1.1. General background

Children with severely dysregulated mood have become diagnostic and therapeutic challenges ~~in~~over the last two decades within the context of pediatric bipolar controversy [1-4]. In view of facilitating research programs researchers at the U.S. National Institute of Mental Health (NIMH) operationalized the criteria of “Severe Mood Dysregulation” (SMD), a syndrome characterized by chronic abnormal levels of anger or sadness, hyperarousal and heightened verbal or physical reactivity [5]. On the grounds of studies conducted in youths with SMD and in view of improving mental health care of youths with chronic irritability, the Disruptive Mood Dysregulation Disorder (DMDD) was introduced as a new diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) within the Depressive Disorders section [6]. Youths with DMDD present chronic irritability combined with severe and recurrent episodes of temper outburst inconsistent with their developmental level at least three times per week and occurring in different settings (e.g., in family, school). These symptoms should persist more than twelve months with no symptom-free period longer than three months and with an initial onset prior to the age of 10. Prevalence of DMDD is reported to be around 8.2% in general population [7-9] and around 26-31% in clinical settings [10,11]. There is much evidence supporting that DMDD symptoms severely affect a youth’s<sup>2</sup> level of social functioning [7,8] and that such negative effects could persist into adulthood [9]. Copeland et al. showed that as adults youths with DMDD present a much higher level of functional impairments (i.e., adverse health outcomes, financial problems, police contact, and low educational attainment) than those with any other psychiatric disorders (e.g., depressive

1 disorders, anxiety disorders, attention deficit hyperactivity disorder ADHD, disruptive disorder,  
2 or substance disorders) [9].  
3  
4  
5  
6

### 7 *1.2. Phenomenology of youths with severely dysregulated mood*

8  
9

10  
11  
12 Mood dysregulation (i.e., severe irritability and high level of anger) is seen as a  
13 transdiagnostic symptom, with a dimensional continuum from its typical expression in normal  
14 development of children and adolescences to severely impairing forms in psychiatric disorders  
15 [12]. In this vein, the development of studies based on specific cognitive and emotional domains  
16 rather than DSM-5 categories of disorders has been encouraged, in particular research aligned  
17 with the framework of the Research Domain Criteria articulated by the NIMH. This strategy  
18 has led to significant improvements in our knowledge of the mechanisms underlying varying  
19 aspects of mood dysregulation in youths. Such progress may ultimately lead to discovering new  
20 markers of the disorder and targets for specific interventions. The study published by Stoddard  
21 et al. [13] provides a good example of how these different levels of analysis can be integrated  
22 in research based on a dimensional view of psychopathology; with the articulation between  
23 impaired neural substrates (i.e., orbitofrontal cortex and amygdala activation), a clinical or  
24 psychological marker (i.e., the result at a face-emotion labelling task), and a therapeutic (i.e.,  
25 computer-based) intervention targeting interpretation bias).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 A different approach has been used in the present review as we specifically focused on  
47 studies where the clinical categories of SMD or DMDD were applied to define the population  
48 of interest. The SMD (i.e., the research syndrome) and then DMDD (i.e., the DMS-5 diagnosis)  
49 criteria were originally developed in view of facilitating the identification of youths with severe,  
50 persistent and functionally impairing forms of irritability, who were likely to fulfil criteria for  
51 different disorders at different times (“diagnostically homeless”) [14]. The development of a  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 specific category for these youths was endorsed due to the need to facilitate access to treatment,  
2 to reduce the rate of misdiagnosis especially early-onset bipolar disorder, and finally to reduce  
3 excessive and inappropriate medication. The inclusion of the DMDD in the 5<sup>th</sup> version of the  
4 DSM has encouraged the development of evidence-based trials which would have been difficult  
5 if mood dysregulation had been operationalized as a dimension. The use of specific disorders  
6 for youths with severely dysregulated mood was encouraged to limit the confusion with early-  
7 onset bipolar disorder and to enhance a more rational use of psychotropic medications (in  
8 particular, mood stabilizers). This issue was regarded as a major public health challenge  
9 considering the trend to overmedication and polypharmacy observed in prepubertal youths [15].  
10 Mood dysregulation can be found in youths with various forms of psychopathology for example  
11 among youths with autistic spectrum disorder and sensory integration issues or in patients with  
12 post-traumatic stress disorder who experience episodic hyperarousal [16]. If a treatment has a  
13 positive impact only in patients with a comorbid psychiatric disorder, its overall benefit in  
14 clinical trial would be under- or overestimated with regards to its prevalence in the sample  
15 studied. The use of a categorical approach can help to explore the heterogeneity of the response  
16 to treatment in DMDD youths, for example through secondary analyses of subgroups with  
17 different associated psychiatric disorders.~~A dimensional view of mood dysregulation in clinical~~  
18 ~~trial is more likely to mask treatment efficacy if researchers fail to consider the heterogeneity~~  
19 ~~of the sample studied and participants' psychiatric comorbidity.~~  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

### 53 *1.3. Validity of SMD and DMDD diagnoses*

54 Evidence for the validity of SMD and later DMDD diagnosis was raised on the ground of  
55 studies exploring the internal and external validity of these disorders, especially data on  
56 discriminant validity [17,18], familial studies [19], psychophysiological and neuroimaging  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 studies [20-23], as well as response to pharmacological treatment [24,14]. However, concerns  
2 have been raised regarding different aspects of the diagnostic validity: the paucity of data  
3 regarding reliability in literature, the difficulty in delineating the normal and abnormal mood  
4 lability in children, and above all the high rate of overlap with others psychiatric disorders,  
5 especially ADHD and ODD [8,10,11]. ~~Besides~~In addition, others aspects of child  
6 psychopathology are still rarely taken into consideration in these studies regarding some aspects  
7 of a child's individual characteristics (e.g., temperamental traits and attachment style) and  
8 environmental backgrounds (e.g., parent-child interaction patterns, possibility of co-occurring  
9 maltreatment). Lastly, significant changes were made in the process of integrating the category  
10 of SMD in DSM-5 including removing the criterion of hyperarousal (e.g., insomnia, agitation,  
11 distractibility, racing thoughts/flight of ideas, pressured speech, and intrusiveness), and the  
12 criterion of low intelligence (IQ<80) from the exclusionary criteria, ~~and as well as~~ lowering the  
13 age of onset from 12 to 10 years old [6]. Such differences are not trivial and could affect the  
14 comorbidity profiles of SMD and DMDD. For example, despite the lack of direct comparison  
15 between the two clinical entities, data suggests that DMDD most often co-occurs with  
16 depressive disorders and ODD and less with ADHD compared to SMD [10].  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 *1.4. Therapeutic strategies*

42  
43  
44  
45  
46 Little is known about effective treatments of SMD and DMDD. The DSM-5 Task Force  
47 suggested that “individual therapy, as well as work with the child's family and/or school [and]  
48 the use of medication to help address specific symptoms” could be useful for DMDD youths  
49 [6]. ~~Although~~However, the use of treatments targeting symptoms without considering the  
50 overall diagnosis has been criticized as it may contribute to the high rates of polypharmacy in  
51 this population [25-27]. Given that SMD and DMDD frequently occur with comorbid  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 psychiatric disorders [8,10,11,28-30], it has been suggested that therapeutic interventions  
2 should primarily focus on treating associated disorders. However, studies examining the benefit  
3 of psychotherapy or pharmacotherapy on mood dysregulation in different psychiatric disorders  
4 are somewhat mixed [31,32]. Galanter et al. [32] found that the higher baseline levels of  
5 psychopathology of children with ADHD and mood dysregulation, compared to those without  
6 prominent mood dysregulation, persisted after intensive multimodal treatments for ADHD,  
7 suggesting the need for additional treatment. In a recent systematic review, Tourian et al.  
8 examined empirical evidence supporting the use of pharmacological treatments for severe  
9 anger/irritability symptoms in youths [4]. They found that pharmacotherapeutic treatment for  
10 both aggression and chronic irritability includes various options, such as antidepressants,  
11 especially selective norepinephrine reuptake inhibitors, mood stabilizers, psychostimulants,  
12 antipsychotics, and alpha-2 agonists. However, such findings are difficult to generalize, since,  
13 as the authors noted, a majority of the study was conducted in small and specific populations  
14 (e.g., youths with developmental disorders). Even if no treatment algorithm for severe persistent  
15 irritability in youths can be derived from this data, that study can be regarded as a first step for  
16 providing evidence-based treatments for children with DMDD as it informed about the  
17 potentially effective treatments. However, in view of meeting the needs of clinician and  
18 researcher, randomized controlled clinical trials (RCTs) ~~that were~~ specifically developed for  
19 youths with SMD or DMDD are required.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 The high rates of comorbidity of SMD and DMDD with externalized disorders  
47 [8,10,11,28-30] raise questions about the best ways to conduct such trials. How should  
48 pharmacological and psychotherapeutic interventions for DMDD be tested within existing  
49 therapeutic strategies for externalized disorders? Which treatments should be allowed in the  
50 control group? How should the severity of mood symptoms be measured? Is the inclusion of  
51 only DMDD subjects without psychiatric comorbidity an acceptable strategy?  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 1 2 *1.5.Aims of the present review* 3 4 5 6

7 In this study, we performed a systematic review to examine psychotherapeutic and  
8 pharmacological interventions for youths presenting SMD or DMDD. Considering the short  
9 delay since the development of DMDD's criteria, such an exhaustive review was not intended  
10 to determine the comparative efficacy and tolerability of these treatments. Our main aim was  
11 rather to describe the benefits and limitations of different research strategies currently  
12 developed for SMD and DMDD with the aim of guiding future research. In this vein, both  
13 published and ongoing studies are presented in this paper.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

## 29 **2. METHODS** 30 31 32 33 34 35

### 36 *2.1.Review* 37 38 39 40 41

42 The systematic review was conducted following the recommendations outlined in the  
43 PRISMA guide (Figure 1) [33]. Titles and abstracts were scanned for relevance. Full texts  
44 were ordered in case of uncertainty to maximize sensitivity. Reference lists of retrieved  
45 systematic reviews were checked. All full texts were checked for eligibility. Any original  
46 study (open trial, double-blind trial whether randomized control or not), case-report, case-  
47 series, meta-analysis and systematic review of pharmacological and non-pharmacological  
48 intervention ~~were~~ was eligible for inclusion in this review. Abstracts and editorials were  
49 excluded. As DMDD was previously known in the literature under the alias of Severe Mood  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Dysregulation (SMD), -studies conducted among youths with SMD were included in the current analysis. Study participants had to be diagnosed with SMD or DMDD, and to be between five and 18 years old, or the mean age of the participants had to fall within the aforementioned age range.

[Insert Figure 1, about here]

## 2.2. Search method for identification of studies

Relevant articles for this study were obtained through Cochrane Central Register of Controlled Trials (CENTRAL), Pubmed, Medline, PsychINFO, PsychINDEXplus and Dissertation Abstracts. Each database was searched from January 2001 to December 2015. In addition, we hand searched reference lists of identified articles and pertinent reviews for additional studies. References from the reviewed articles were also screened to find more articles of interest. Furthermore, clinical trials registries (<http://www.clinicaltrials.gov> of the US National Institutes of Health and the WHO International Clinical Trials Registry Platform, ICTRP) were searched for ongoing trials. We used the following search terms: “Disruptive mood dysregulation disorder” OR “Severe mood dysregulation” OR “Temper outburst” AND “Therapeutics” OR “Clinical protocols” OR “Treatment” OR “Pharmacotherapy” OR “Psychotherapy”. Authors independently screened potential studies, after reading the full article, for inclusion in the review, and the results were collated. The systematic review yielded 86 hits, with 29 being a duplicate; 21 hits could be excluded based on the information in the title or abstract. The full texts of 36 hits were critically reviewed leading to exclusion of another 21 articles because these were only reviews or comments and no new original data were included; or the research ~~were~~ was not conducted in DMDD/SMD youths. A ~~total~~ list of

15 studies ~~were~~ was generated: eight completed studies (one case report, four open pilot studies and three RCTs) and seven ongoing studies found in trial registries.

### 2.3. Data and analysis

Data and information extractions from each study were performed independently by the two first authors. For each study under review, year of publication and references were extracted. In order to summarize the treatment attributes, in each report we collected the following information: description of medication, length of treatment, and dose received. Information on additional or adjunctive interventions was also collected. Additional information regarding the attributes of participants enrolled in the studies were extracted and were as follows: age, gender, how the diagnosis was made, treatment setting, comorbid conditions, sociodemographic data, and screening tools used. Although a meta-analytic review has been preferable, the diversity of statistical methods and measurement practices across studies did not allow for the calculation of pooled effect size. We categorized the level of evidence presented in each paper using the United States Preventive Services Task Force (USPSTF) criteria [35]. According to this schematic, level I evidence denotes having at least one well-designed RCT supporting a treatment's possible efficacy. Level II-1 requires a well-designed controlled trial without randomization, level II-2 requires at least one well-designed cohort or case-control study, and level II-3 requires a multiple time series design. We excluded level III evidence (opinions of respected authorities based on clinical experience or descriptive studies) from the present review.

## 3. RESULTS



### 3.1. Psychotherapeutic interventions for DMDD

#### 3.1.1. Completed studies

Only three studies were eligible for the review (Table 1): an exploratory analysis from a controlled study of multiple interventions for ADHD children [36], the subsequent open uncontrolled feasibility study conducted by the same research team on youths with ADHD and SMD [37], and an open pilot uncontrolled study on DMDD youths [13].

Waxmonsky et al. (2008) conducted secondary analysis of data from the 2003-2004 ADHD Summer Treatment Program (ADHD-STP), a research program for children aged 5–12 in the form of an intensive 9-week therapeutic summer camp [38]. ~~Initial-~~The initial study aimed to assess the relative efficacy and synergistic effects of differential doses of behavioural and pharmacologic interventions in ADHD youths. Among the 106 participants, 33 fulfilled NIMH criteria for SMD (mean age  $8.0 \pm 2.1$  years and  $8.7 \pm 2.0$  years for non-SMD group). The behavioral intervention consisted of daily social skills training and a reward-based learning program (detailed in [39]). This treatment varied in frequency every three weeks with the order: no behavior modification, low-intensity (i.e., weekly sessions) and high-intensity (i.e., daily sessions). Clinicians rating mood symptoms were not blind to treatments status. There was no evidence of differential treatment efficacy or tolerability on ADHD symptoms between the participants with and without SMD, even though those with SMD were more likely to remain significantly impaired at home than non-SMD subjects. After nine weeks, multimodal treatment produced a 34% reduction in YMRS ratings in SMD subjects ( $p < 0.001$ ).

In an open-label uncontrolled rater-blind study, Waxmonsky and colleagues examined the feasibility and preliminary efficacy of a psychotherapeutic program that integrated

1 components of CBT focusing on affect regulation and parent training intervention [37]. The  
2 seven included children (mean age  $8.7 \pm 1.6$  years) presented ADHD and the NIMH criteria  
3 for SMD. All participants were male. All of the children took stimulant medication for ADHD  
4 and all but two participants were currently receiving counselling services. SMD symptoms  
5 were assessed using the depression and mania modules from the Washington University  
6 Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS). The  
7 sessions consisted of 105-minute concurrent parent and child meetings. Six of the seven  
8 ~~(86%)~~ families (86%) completed at least seven of the nine weeks in the program. Over the 16  
9 week follow-up, participants showed a reduction in the level of depressive symptoms (CDRS-  
10 R,  $d=1.17$ ) and externalizing symptoms (ADHD:  $d=0.30$ ; ODD:  $d=0.26$ ; CD:  $d=0.27$ ).  
11 Authors interpreted the reduction in YMRS score ( $d=0.81$ ) as an improvement in mood  
12 lability among participants.

13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29 In an open-label uncontrolled study, Stoddard and colleagues examined the  
30 preliminary efficacy of an intervention based on four sessions of computer-based Hostile  
31 Interpretation Therapy [13]. The 14 included children (mean age  $14.1 \pm 2.4$  years) ~~who~~  
32 presented DMDD. The gender ratio was 8:6 for female. DMDD symptoms were assessed  
33 using the Affective Reactivity Index and the Clinical Global Impression- Improvement scale.  
34 Training is designed to shift interpretation of ambiguous morphs bias toward happy  
35 judgments. Ten subjects completed an implicit functional MRI face-emotion processing task.  
36 Active training is associated with a shift in balance point toward more happy judgments (use  
37 as a proxy for hostile attribution bias) ( $\beta = 2.25$  morphs). Evidence suggests that active  
38 training may be associated with decreased irritability ( $\beta = -1.57$  in parent-report ARI score, no  
39 significant change in self-report) and changes in activation patterns in the lateral orbitofrontal  
40 cortex.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3.1.2. Ongoing studies

Four trials were found searching the clinical trials registries that are underway.

The group from Yale University started a randomized open-label controlled study in May 2013 to examine feasibility and preliminary efficacy of Dialectical Behaviour Therapy adapted to children (DBT-C) (NCT01862549). The study targets to include 60 7–12 years old children meeting DSM-5 criteria for DMDD. Participants are randomly assigned to receive one of two treatments for 30 weeks: DBT-C or enhanced care (active control condition). Participants on the DBT-C arm received two pre-treatment sessions and 24 treatment sessions with once per week meetings, including 30 min individual child therapy, 20 min meeting with a caregiver and 40 min of skills training with both. Enhanced care consists of supportive individual psychotherapy, such as cognitive behavioural skills training and adjunctive family interventions (e.g., parenting skills training, structuring household environment, and safety planning). After the acute 32-week intervention period, 3-month follow-up assessments are conducted. The primary outcome is the attendance and drop-out rate measure, the level of satisfaction and compliance at 32 weeks; secondary end-points are reduction in DMDD symptoms and disruptive problems, psychosocial functioning and mental health service use. Estimated primary completion date of the study is July 2015.

The second ongoing study investigates the feasibility and acceptability of Interpersonal Psychotherapy for youths with SMD (IPT-SMD). A monocentric uncontrolled open-label study (NCT01591564) started in May 2012 and targeted to include five subjects who meet NIMH criteria for SMD. Youth receive weekly therapy sessions for 16 weeks and then bi-weekly sessions until week 20. Parent sessions are also included. The primary outcome is the retention rate and secondary end-points include various measures of clinical improvement. The investigators hypothesized that retention rates will be above 80% and the

1 satisfaction score above six on a seven point scale. Although the results of this research have  
2 not yet been published, the same research team started a randomized rater-blind controlled  
3 study in October 2013 to test the effectiveness of Interpersonal Psychotherapy for Youth with  
4 Mood and Behaviour Dysregulation (IPT-MBD) on a more important sample size and allow  
5 for a longer follow-up time (NCT01962623). IPT-MBD is nearly identical to IPT-SMS,  
6 except that bi-weekly sessions last until week 24. This study targets to include 44 youths  
7 between 13 and 17 years meeting criteria for SMD. Primary and secondary outcomes are  
8 similar to prior research. Estimated primary completion date of the study is August 2016.

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19 A monocentric open-label uncontrolled study is underway since August 2015 to  
20 compare the efficacy of CBT and Interpretation Bias Training (IBT) on DMDD  
21 (NCT02531893). IBT is a newly developed computer-based training focusing on the socio-  
22 emotional information process impairments described in youths with severe irritability (e.g.,  
23 anger attribution bias). IBT is performed during 14 sessions over 10 weeks (four sessions in  
24 four days, followed by eight weekly booster sessions after a two weeks delay) and CBT  
25 consists of 12-16 weekly meetings. Primary outcomes are improvement in the Clinical Global  
26 Impressions–Improvement score (CGI-I) and changes in irritability score using the Affective  
27 Reactivity Index (ARI). A four-week wash-out period is planned for those who participate in  
28 both treatments. Estimated primary completion date of the study is August 2019.

29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44 [Insert Table 1 about here]

### 45 46 47 48 49 50 *3.2. Pharmacological treatments for DMDD*

#### 51 52 53 54 55 3.2.1. Completed studies

56  
57  
58 Only four completed pharmacological ~~completed~~ studies were eligible for the review  
59 (Table 1).  
60  
61  
62  
63  
64  
65

1  
2 In the secondary analysis of data from the 2003-2004 ADHD Summer Treatment  
3 Program, Waxmonsky et al. examined the effectiveness of different doses of methylphenidate  
4 (MPH) in SMD symptoms in children aged 5–12 with ADHD [36]. All subjects in each  
5 psychotherapeutic group were treated with increasing MPH doses (placebo, 0.15 mg/kg, 0.3  
6 mg/kg, and 0.6 mg/kg). As mentioned above, multimodal treatment produced a 34% reduction  
7 in YMRS ratings in SMD subjects.  
8  
9

10  
11  
12  
13  
14 Dickstein et al. led a placebo-controlled randomized trial to test the efficacy of lithium  
15 in SMD [24]. At admission 7–17 year old youths with SMD were tapered off previously  
16 prescribed medication. Those who continued to meet SMD criteria after a 2-week, single-  
17 blind, placebo run-in were randomized to a 6-week double-blind trial of either lithium (n=14)  
18 or placebo (n=11). The primary outcome measure was the CGI-I score less than four at trial's  
19 end. Magnetic resonance spectroscopy (MRS) was performed in all participants to measure  
20 biological markers known to be associated with lithium activity (i.e., myoinositol, N-acetyl-  
21 aspartate and combined glutamate). Almost half of the subjects (n=20) were not randomized  
22 due to significant clinical improvement during the placebo run-in. Among randomized  
23 patients, there were no significant between-group differences in either clinical or MRS  
24 outcome measures.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 Krieger et al. conducted an open-label trial to determine the effectiveness of  
42 risperidone on youths with DMDD [40]. Of the 97 subjects initially assessed for severe  
43 irritability symptoms only 21 met DMDD criteria and were finally enrolled in the study.  
44 Evaluations were performed at baseline and weeks 2, 4, 6, and 8. The primary outcome  
45 measures were the Aberrant Behaviour Checklist–Irritability Subscale (ABC-Irritability)  
46 score, the CGI-I score and the severity of comorbid conditions. Risperidone was titrated from  
47 0.5 to 3 mg/day in the first two weeks. A significant reduction of the ABC-Irritability score  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 was observed after risperidone use. Authors reported a clinically significant improvement in  
2 ADHD and depression symptoms, as well as in global functioning.  
3

4 Parmar et al. reported the case of a 15-year old boy presenting a DMDD and ADHD  
5 successfully treated with 50 mg of naltrexone [41]. Previous treatments received were  
6 methylphenidate, guanfacine extended release, and aripiprazole at 5 mg to 15 mg once daily.  
7 Tolerability profile was good, except for an increased sedation. The lack of evidence  
8 supporting long-term naltrexone justified the decision to stop the drug after three months.  
9 Authors described a resurgence of patient's aggressive symptoms after drug discontinuation,  
10 as well as an improvement after drug reintroduction.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### 24 3.2.2. Ongoing studies

25 Three pharmacological trials in SMD/DMDD youths are underway.

26 Leibenluft et al. started in November 2008 a trial to determine the feasibility and  
27 acceptability of MPH combined or not with citalopram, a selective serotonin re-uptake  
28 inhibitor (SSRI) antidepressant, in youths with SMD (NCT00794040). A wash-out period is  
29 followed by a 5-week dose stabilization phase of methylphenidate. Participants are then  
30 randomly and blindly assigned to receive citalopram (target dose: 20-40 mg/day) or a placebo.  
31 After eight weeks subjects were invited to participate in an open treatment phase for around  
32 seven weeks. This study targets to include 160 7-17 year old youths who meet NIMH criteria  
33 for SMD. The primary outcome measures are the ABC-Irritability score and the CGI-I score.  
34 Estimated primary completion date of the study is October 2016.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 In January 2013, Mc Gough et al. started a preliminary study to evaluate the feasibility  
52 and acceptability of lisdexamfetamine, a psychostimulant, combined or not with fluoxetine, a  
53 SSRI antidepressant, in youths with SMD (NCT01714310). Participants have 4 weeks open  
54 titration with lisdexamfetamine to optimal dose, followed by double-blind randomization  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 to fluoxetine or placebo in combination with optimized lisdexamfetamine for an additional  
2 eight weeks. The investigators target to include 50 children aged 7–17 years old meeting  
3 NIMH criteria for SMD (n=25, in each arm). The primary outcome is the Clinical Global  
4 Impression-Improvement-Severe Mood Dysregulation, a categorical clinician rating of overall  
5 improvement from baseline, modified by the NIMH to assess specific domains pertinent to  
6 SMD symptoms; secondary end-points are improvement in anxiety and mood symptoms,  
7 emotion regulation and disruptive problems, changes on EEG profiles of cortical activity from  
8 baseline at week 12. Estimated primary completion date of the study is July 2015.

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Gothelf et al. are conducting an ongoing trial since February 2014 in view of  
comparing the feasibility and acceptability of MPH vs. risperidone in the treatment of youths  
with both ADHD and DMDD (NCT02063945). Participants are randomly assigned to one of  
the two arms. The primary outcome measure is the reduction of aggressive behaviour  
(measured with the Retrospective Modified Overt Aggression Scale) after an 8-week  
treatment. This study targets to include 70 youths (5-18 year old) who meet DSM-5 criteria  
for both DMDD and ADHD. Estimated primary completion date of the study is February  
2016.

[Insert Table 2, about here]

[Insert Table 3, about here]

## 4. DISCUSSION

### *4.1. Treatment efficacy and tolerability*

1 At present there is only very limited empirical evidence for interventions in SMD or  
2 DMDD youths. Behaviour therapy or CBT associated with parental training showed a  
3  
4 potential for symptom reduction and improvement of global functioning among youths with  
5  
6 both ADHD and SMD [36,37]. This is in line with the efficacy of parental guidance  
7  
8 previously reported in youths with ADHD and behaviour problems [42]. In one study, the  
9  
10 analyses were performed post-hoc in a subsample of the overall randomized group [36], thus  
11  
12 calling successful randomization into question. In the second analysis, the small sizes of the  
13  
14 sample make it difficult to prevent from generalizing to other population [37]. One pilot study  
15  
16 shows encouraging results for the possible benefit of Interpretation Bias Therapy [13]. The  
17  
18 rationale for the development of IBT in DMDD (also evaluated in NCT02531893) is based on  
19  
20 the difficulties in performing specific cognitive tasks reported in this population (e.g.,  
21  
22 attentional bias to threat, poor inhibitory control) [20]. Four controlled studies are currently  
23  
24 under way to test the effects of psychotherapeutic interventions. The benefit of DBT or IPT in  
25  
26 DMDD (evaluated in NCT01862549, NCT01591564, NCT01962623) is hypothesised from  
27  
28 available evidence for positive effects in youths with other internalizing disorders [43-46].  
29  
30 DBT, historically developed for chronically suicidal adults with borderline personality  
31  
32 disorder, was regarded as effective to target mood dysregulation across a range of diagnoses  
33  
34 [44]. Empirical studies support the use of DBT with adolescents diagnosed with depression  
35  
36 [44], bipolar disorder [45] and ODD [47]. IPT is a brief psychotherapy successfully developed  
37  
38 to target depressive symptoms in adolescents [46]. In addition to the patient's mood  
39  
40 symptoms, focus is placed on the interpersonal context in which they occur. The greater  
41  
42 emphasis of IPT on basic social skills and on learning to negotiate relationally could be  
43  
44 particularly relevant to address emotional reactivity and poor tolerance to frustration in  
45  
46 DMDD youths.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



Concerning a pharmacological approach, four studies were identified [36,24,40,41].

1  
2 Lithium carbonate was not found to be more effective than placebo in young inpatients with  
3  
4 SMD [24]. However, preliminary results support a positive effect of risperidone for  
5  
6 decreasing irritability and externalized symptoms in SMD youths [40]. A possible effect of  
7  
8 naltrexone (one single case only) is reported in a 15-year old boy with ADHD and DMDD  
9  
10 [41]. Psychostimulant was found partly effective on youths with ADHD and SMD to treat  
11  
12 SMD symptoms [36]. This finding is consistent with meta-analyses demonstrating an efficacy  
13  
14 of psychostimulant on irritability [48] and in reactive aggression [49] in ADHD youths.  
15  
16 However, in line with a prior study [32], Waxmonsky et al. [36] noted that psychostimulant  
17  
18 remains only partially effective in this patient. In the ADHD-STP study, only 6% of youths  
19  
20 with ADHD and SMD were in remission at endpoint, compared to 27% in the control group  
21  
22 (ADHD without SMD) [36]. Such findings build a rationale for the development of “add-on”  
23  
24 pharmacological strategy; i.e., the use of a second line of medication (different from  
25  
26 psychostimulant) in youths with both ADHD and SMD/DMDD criteria. Currently, two  
27  
28 controlled studies are under way to further clarify whether adding an SSRI antidepressant can  
29  
30 decrease DMDD symptomatology (NCT00794040, NCT01714310). Following another  
31  
32 pharmacological approach, one study tests the comparative efficacy of an atypical  
33  
34 antipsychotic and a psychostimulant as a first line treatment in youths with ADHD and  
35  
36 DMDD (NCT02063945). In particular, risperidone seems to be a promising molecule ([40],  
37  
38 NCT02063945) in regards to its uses in the treatment of severe irritability in youths with other  
39  
40 psychiatric disorders (e.g., autism spectrum disorder or intellectual disability) [4]. Of note, no  
41  
42 study was conducted to test the possible benefit of selective norepinephrine reuptake  
43  
44 inhibitors, mood stabilizers, or alpha-2 agonists, despite preliminary studies showing a  
45  
46 possible benefit of these medications for youths with severe irritability [4].  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 4.2.Limitations

Several methodological weaknesses of the studies available for review may be partly responsible for the limited knowledge available in this field. We identified three sources that presented level II-1 evidence, one for level II-2 evidence, and three for level II-3 evidence. No source for level I evidence study ~~were~~was found. In the next paragraphs we discuss the principal limitation of these studies and suggest possible improvements.

### 4.2.1. Eligibility criteria

Criteria for DMDD have only been defined since May 2013, i.e. the publishing of the DSM-5 [6], whereas NIMH criteria for SMD have been operationalized since 2001 [34]. Consequently, the participant eligibility was based on SMD criteria in most of the reviewed studies. Results of published studies focusing on SMD youths should not be extrapolated to youths with DMDD without caution, as the two constructs are not similar. As the “hyperarousal” criterion exists for SMD but not for DMDD, treatments that are effective in decreasing hyperarousal symptoms (e.g., benzodiazepines) may be mistakenly regarded as effective for DMDD. As the profile of comorbid psychiatric disorders of SMD and DMDD can differ slightly [10] the impact of specific treatments (e.g., psychostimulant) on DMDD could be under- or overestimated if data are extrapolated from studies conducted in SMD youths. We suggest that only the DMDD category should be used in future research, and if not, detailed analysis of treatment response for each symptom should be provided.

The rate of comorbidity between DMDD and externalizing disorders ~~were~~was high in all studies and especially between DMDD and ADHD (ranging from 71% to 100%) [24,41,40]. As diagnostic criteria overlap between these two disorders, studies conducted in youths with both ADHD and DMDD should examine whether the improvement in DMDD

1 symptoms is not due to the impact of the treatment on shared symptoms. Waxmonsky et al.  
2 noted that 23% of the total severity score change occurred in items overlapping with ADHD  
3 symptoms [36]. Again, item-by-item analysis that was not performed in other studies could be  
4 useful.  
5  
6  
7  
8

9 This review highlights the importance of using both a measure of general  
10 improvement, such as the CGI-I, and a specific measure for symptoms severity. There are two  
11 reasons why the scales used to measure the main outcomes may be inappropriate. First, some  
12 of them were developed for manic symptoms (e.g., the YMRS) [36,37]; therefore, a decrease  
13 in total score may reflect a reduction in items such as loss of appetite or sleep changes which  
14 are not associated with DMDD. Second, other authors used subscores of scales that were not  
15 originally developed for irritability (e.g., the ABC—Irritability or the PANSS subscore)  
16 [24,40]. Content validity of such subscales is problematic as it may not cover all aspects of  
17 DMDD leading to biased results, while their poor reliability increases the risk of erroneous  
18 conclusion [50]. Moreover, as noted by Leibenluft, irritability, aggressive behaviors and  
19 hostility are embedded by distinct, even if somewhat related, pathophysiological process [51];  
20 ~~and~~ they therefore should be regarded as different therapeutic targets. At best, authors should  
21 use scales specifically developed to measure irritability and temper outburst such as the  
22 Affective Reactivity Index [52] or the Child Affective Lability Scale [53].  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Exclusion criteria regarding intellectual disability, autism spectrum disorder and  
45 distinct manic episode were respected in line with NIMH and APA recommendations [5,6].  
46 Of note, some studies included subjects with suicidal ideations (NCT01862549), whereas  
47 others did not (NCT01591564, NCT01962623). The status of medication was discussed in all  
48 except one study (NCT02531893). Authors recommend that psychotropic medication should  
49 not be used in a time period ranging from four weeks (NCT01591564) to six months [40]. At  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

best, a period of medication withdrawal should be conducted after the period of inclusion (NCT00794040, [40]).

#### 4.2.2. Design

A high level of placebo response was observed in the only placebo-controlled study [24]. This finding is consistent with the substantial decline in symptomatology scores experienced by the placebo group in RCT-DB of adolescents with mood disorders, such as mania [54,55] or depressive disorder [56,57]. It has been noted that most of the placebo effect in antidepressant trials occurs during the first two weeks of treatment [58], possibly due to the therapeutic effects of meeting with health professionals [56]. Interestingly, Krieger et al. observed a slight increase in the level of symptomatology at four weeks compared to it at two weeks of treatment [40]. It could be somewhat comparable to the “honey moon” observed in SMD young patients who exhibited significant improvement in symptoms after admission that have not persisted with time [36], or the rapid improvement in non-medicated youths admitted ~~in~~to hospitalization for severe rage episodes [14]. On the one hand, we suggest that authors examine how DMDD-symptom scores change gradually over the trial, to make sure than the decline does not occur only at the very beginning of the treatment after the inclusion. On the other hand, a run-in period before randomization may be useful to distinguish a “real” pharmacological effect from the positive impact of non-specific interventions (e.g., supportive psychotherapy, cares provided by a structured milieu, or the removal from a stressful environment) [56,57], in particular when the subject is randomized just after admission in a psychiatric ward.

#### 4.2.3. Measures of tolerability and acceptance

1 Tolerability and acceptance were systematically measured with specific scales in all  
2 pharmacological studies. Considering the fact that irritability is both a symptom of DMDD  
3 and a possible side effect of many psychotropic medications, especially SSRI [59] and  
4 stimulant [60], it may be useful to determine whether a dose-effect relationships occurs  
5 between the treatment dose or duration and the severity of side effects (as shown in [40]).  
6  
7 Paraclinical examinations were adequately performed to examine possible metabolic side  
8 effects of atypical antipsychotic agents [40], or the effect of lithium carbonate on thyroid  
9 function [24].  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 *4.3. Clinical and research implications*

23  
24  
25  
26

27 In this research we reviewed the evidence for supporting the clinical benefits of  
28 psychotherapeutic and pharmacological treatments for DMDD/SMD youths. Further research  
29 would help to clarify the mechanisms involved at different levels (psychological, cognitive or  
30 relational). As discussed in the introduction, we thought that complementary approaches are  
31 also needed, in particular exploring the positive impact of such treatments on a clinical  
32 construct such as a youth's emotional dysregulation while adopting a trans-nosological view.  
33 Severe emotional dysregulation is a key characteristic of SMD/DMDD, but it is also seen as a  
34 core symptom for other DSM-5 disorders, such as trauma-related disorders (e.g., complex  
35 PTSD, reactive attachment disorder), borderline personality disorder (BPD), or intermittent  
36 explosive disorders in DSM-5.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51 Future research should reveal whether, and to what extent, the severely dysregulated  
52 prepubertal youths presenting SMD/DMDD criteria develop other psychiatric disorders in  
53 adolescence (especially borderline personality disorder). In turn, findings from clinical trials  
54 conducted in youths with mood dysregulation-related disorders can inform future projects for  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 SMD/DMDD therapeutic studies. For example, antipsychotics that have shown beneficial  
2 effects in the short-term on cognitive-perceptual symptoms, anger, and mood lability in those  
3 with BPD [61] have not demonstrated effectiveness for longer use. Interestingly,  
4 psychotherapies that focus on the development of secure bounds and relational difficulties  
5 (e.g., Dialectical Behavioral Therapy or Mentalizing-Based Therapy) exhibit the highest level  
6 of evidence for youths with BPD features [62]. The interplay between the development of  
7 emotional and social abilities throughout childhood, as stressed in various theoretical models  
8 (e.g., the socio-emotional developmental model, the psychodynamic view of object relations  
9 theory, or the attachment theory), highlights the possible benefit of promoting the youths'  
10 social skills while caring for mood dysregulation. Surprisingly no study was devoted to the  
11 impact of family interventions in SMD/DMDD youths. The importance of parent-child  
12 quality of interactions on the emergence of child's emotion regulation strategies has however  
13 although been supported in epidemiological and clinical studies (for a review [63]).  
14 Moreover, the bidirectional relationships between a child's degree of emotional distress and  
15 the parental level of adjustment has been regarded as a key mechanism to understand the  
16 persistence of symptoms [16].

#### 4.4. Conclusion

47 The two current pharmacological strategies tested for SMD and DMDD patients are a  
48 monotherapy of psychostimulants or atypical antipsychotics and the use of SSRI as an add-on  
49 therapy in youths with comorbid ADHD and treated with psychostimulant. Psychotherapeutic  
50 treatments currently being tested are based on methods previously developed for depression  
51 (e.g., IPT, DBT) and/or youths with ADHD and behavioural problems (e.g., parental  
52 behavioural guidance). The overall level of available evidence remains dramatically poor  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 regarding clinical needs, in particular with regards to the size of the sample studied and the  
2 heterogeneity of inclusion criteria. Moreover, the lack of follow-up above 8 weeks prevents  
3 current studies from being conclusive for the impact of treatment over a short-term duration.  
4  
5 Future studies will further clarify the effectiveness of therapeutic interventions for DMDD  
6  
7 individuals. Such studies should (i) be conducted in large multi-site studies, (ii) with specific  
8  
9 and standardized procedures to measure DMDD symptom improvements, and (iii) include a  
10  
11 run-in period to limit placebo effect.  
12  
13  
14  
15  
16  
17  
18

19 **LIST OF ABBREVIATIONS USED:** Disruptive Mood Dysregulation Disorder (DMDD);  
20  
21 Severe Mood Dysregulation (SMD); Attention Deficit with Hyperactivity Disorder (ADHD);  
22  
23 Oppositional Defiant Disorder (ODD); Conduct Disorder (CD); Separation Anxiety Disorder  
24  
25 (SAD); Anxiety Disorders (AD); Major Depressive Disorder (MDD); National Institute of  
26  
27 Mental Health (NIMH); Cognitive Behavioral Therapy (CBT); Behavioral Parental Training  
28  
29 (BPT); Disruptive Behavior Disorders Interview (DBD); Washington University Kiddie  
30  
31 Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS); Clinical Global  
32  
33 Impressions–Improvement (CGI-I); Clinical Global Impressions–Severity (CGI-S)  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 REFERENCES

- 45  
46 1. Masi G, Pisano S, Milone A, Muratori P (2015) Child behavior checklist dysregulation profile  
47 in children with disruptive behavior disorders: A longitudinal study. *J Affect Disord* 186:249-253.  
48 doi:10.1016/j.jad.2015.05.069  
49 2. Roy AK, Lopes V, Klein RG (2014) Disruptive Mood Dysregulation Disorder: A New Diagnostic  
50 Approach to Chronic Irritability in Youth. *American Journal of Psychiatry* 171 (9):918-924.  
51 doi:doi:10.1176/appi.ajp.2014.13101301  
52 3. Consoli A, Cohen D (2013) Manic-like symptoms in youths: Diagnosis issues and  
53 controversies. *Neuropsychiatrie de l'Enfance et de l'Adolescence* 61:154-159  
54 4. Tourian L, LeBoeuf A, Breton JJ, Cohen D, Gignac M, Labelle R, Guile JM, Renaud J (2015)  
55 Treatment Options for the Cardinal Symptoms of Disruptive Mood Dysregulation Disorder. *J*  
56 *Can Acad Child Adolesc Psychiatry* 24 (1):41-54  
57 5. Leibenluft E, Blair RJ, Charney DS, Pine DS (2003) Irritability in pediatric mania and other  
58 childhood psychopathology. *Ann N Y Acad Sci* 1008:201-218  
59  
60  
61  
62  
63  
64  
65



6. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. American Psychiatric Association,
7. Dougherty LR, Smith VC, Bufferd SJ, Carlson GA, Stringaris A, Leibenluft E, Klein DN (2014) DSM-5 disruptive mood dysregulation disorder: correlates and predictors in young children. *Psychol Med* 44 (11):2339-2350. doi:10.1017/S0033291713003115
8. Copeland WE, Angold A, Costello EJ, Egger H (2013) Prevalence, comorbidity, and correlates of DSM-5 proposed disruptive mood dysregulation disorder. *Am J Psychiatry* 170 (2):173-179. doi:10.1176/appi.ajp.2012.12010132
9. Copeland WE, Shanahan L, Egger H, Angold A, Costello EJ (2014) Adult diagnostic and functional outcomes of DSM-5 disruptive mood dysregulation disorder. *Am J Psychiatry* 171 (6):668-674. doi:10.1176/appi.ajp.2014.13091213
10. Axelson D, Findling RL, Fristad MA, Kowatch RA, Youngstrom EA, Horwitz SM, Arnold LE, Frazier TW, Ryan N, Demeter C, Gill MK, Hauser-Harrington JC, Depew J, Kennedy SM, Gron BA, Rowles BM, Birmaher B (2012) Examining the proposed disruptive mood dysregulation disorder diagnosis in children in the Longitudinal Assessment of Manic Symptoms study. *J Clin Psychiatry* 73 (10):1342-1350. doi:10.4088/JCP.12m07674
11. Margulies DM, Weintraub S, Basile J, Grover PJ, Carlson GA (2012) Will disruptive mood dysregulation disorder reduce false diagnosis of bipolar disorder in children? *Bipolar Disord* 14 (5):488-496. doi:10.1111/j.1399-5618.2012.01029.x
12. Lochman JE, Evans SC, Burke JD, Roberts MC, Fite PJ, Reed GM, de la Pena FR, Matthys W, Ezpeleta L, Siddiqui S, Elena Garralda M (2015) An empirically based alternative to DSM-5's disruptive mood dysregulation disorder for ICD-11. *World Psychiatry* 14 (1):30-33. doi:10.1002/wps.20176
13. Stoddard J, Sharif-Askary B, Harkins EA, Frank HR, Brotman MA, Penton-Voak IS, Maoz K, Bar-Haim Y, Munafo M, Pine DS, Leibenluft E (2016) An Open Pilot Study of Training Hostile Interpretation Bias to Treat Disruptive Mood Dysregulation Disorder. *J Child Adolesc Psychopharmacol* 26 (1):49-57. doi:10.1089/cap.2015.0100
14. Carlson GA, Potegal M, Margulies D, Gutkovich Z, Basile J (2009) Rages--what are they and who has them? *J Child Adolesc Psychopharmacol* 19 (3):281-288. doi:10.1089/cap.2008.0108
15. Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M (2007) National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. *Arch Gen Psychiatry* 64 (9):1032-1039. doi:10.1001/archpsyc.64.9.1032
16. Stringaris A, Taylor E (2015) Disruptive Mood: Irritability in Children and Adolescent.
17. Brotman MA, Schmajuk M, Rich BA, Dickstein DP, Guyer AE, Costello EJ, Egger HL, Angold A, Pine DS, Leibenluft E (2006) Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. *Biol Psychiatry* 60 (9):991-997. doi:10.1016/j.biopsych.2006.08.042
18. Stringaris A, Baroni A, Haimm C, Brotman M, Lowe CH, Myers F, Rustgi E, Wheeler W, Kayser R, Towbin K, Leibenluft E (2010) Pediatric bipolar disorder versus severe mood dysregulation: risk for manic episodes on follow-up. *J Am Acad Child Adolesc Psychiatry* 49 (4):397-405
19. Brotman MA, Kassem L, Reising MM, Guyer AE, Dickstein DP, Rich BA, Towbin KE, Pine DS, McMahon FJ, Leibenluft E (2007) Parental diagnoses in youth with narrow phenotype bipolar disorder or severe mood dysregulation. *Am J Psychiatry* 164 (8):1238-1241. doi:10.1176/appi.ajp.2007.06101619
20. Guyer AE, McClure EB, Adler AD, Brotman MA, Rich BA, Kimes AS, Pine DS, Ernst M, Leibenluft E (2007) Specificity of facial expression labeling deficits in childhood psychopathology. *J Child Psychol Psychiatry* 48 (9):863-871. doi:10.1111/j.1469-7610.2007.01758.x
21. Rich BA, Carver FW, Holroyd T, Rosen HR, Mendoza JK, Cornwell BR, Fox NA, Pine DS, Coppola R, Leibenluft E (2011) Different neural pathways to negative affect in youth with pediatric bipolar disorder and severe mood dysregulation. *J Psychiatr Res* 45 (10):1283-1294. doi:10.1016/j.jpsychires.2011.04.006
22. Dickstein DP, Gorrostieta C, Ombao H, Goldberg LD, Brazel AC, Gable CJ, Kelly C, Gee DG, Zuo X-N, Castellanos FX, Milham MP (2010) Fronto-Temporal Spontaneous Resting State Functional Connectivity in Pediatric Bipolar Disorder. *Biological Psychiatry* 68 (9):839-846. doi:<http://dx.doi.org/10.1016/j.biopsych.2010.06.029>



23. Brotman MA, Rich BA, Guyer AE, Lunsford JR, Horsey SE, Reising MM, Thomas LA, Fromm SJ, Towbin K, Pine DS, Leibenluft E (2010) Amygdala activation during emotion processing of neutral faces in children with severe mood dysregulation versus ADHD or bipolar disorder. *Am J Psychiatry* 167 (1):61-69. doi:10.1176/appi.ajp.2009.09010043
24. Dickstein DP, Towbin KE, Van Der Veen JW, Rich BA, Brotman MA, Knopf L, Onelio L, Pine DS, Leibenluft E (2009) Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. *J Child Adolesc Psychopharmacol* 19 (1):61-73. doi:10.1089/cap.2008.044
25. Comer JS, Olfson M, Mojtabai R (2010) National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. *J Am Acad Child Adolesc Psychiatry* 49 (10):1001-1010. doi:10.1016/j.jaac.2010.07.007
26. Olfson M, Crystal S, Huang C, Gerhard T (2010) Trends in antipsychotic drug use by very young, privately insured children. *J Am Acad Child Adolesc Psychiatry* 49 (1):13-23
27. Parens E, Johnston J, Carlson GA (2010) Pediatric mental health care dysfunction disorder? *The New England journal of medicine* 362 (20):1853-1855. doi:10.1056/NEJMp1003175
28. Sparks GM, Axelson DA, Yu H, Ha W, Ballester J, Diler RS, Goldstein B, Goldstein T, Hickey MB, Ladouceur CD, Monk K, Sakolsky D, Birmaher B (2014) Disruptive mood dysregulation disorder and chronic irritability in youth at familial risk for bipolar disorder. *J Am Acad Child Adolesc Psychiatry* 53 (4):408-416. doi:10.1016/j.jaac.2013.12.026
29. Efron D, Sciberras E, Anderson V, Hazell P, Ukoumunne OC, Jongeling B, Schilpzand EJ, Bisset M, Nicholson JM (2014) Functional status in children with ADHD at age 6-8: a controlled community study. *Pediatrics* 134 (4):e992-e1000. doi:10.1542/peds.2014-1027
30. Mulraney M, Schilpzand EJ, Hazell P, Nicholson JM, Anderson V, Efron D, Silk TJ, Sciberras E (2015) Comorbidity and correlates of disruptive mood dysregulation disorder in 6-8-year-old children with ADHD. *Eur Child Adolesc Psychiatry*. doi:10.1007/s00787-015-0738-9
31. Fernandez de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A (2015) Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA). *J Am Acad Child Adolesc Psychiatry* 54 (1):62-70.e63. doi:10.1016/j.jaac.2014.10.006
32. Galanter CA, Carlson GA, Jensen PS, Greenhill LL, Davies M, Li W, Chuang SZ, Elliott GR, Arnold LE, March JS, Hechtman L, Pelham WE, Swanson JM (2003) Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. *J Child Adolesc Psychopharmacol* 13 (2):123-136. doi:10.1089/104454603322163844
33. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 339:b2535. doi:10.1136/bmj.b2535
34. Leibenluft E (2011) Severe Mood Dysregulation, Irritability, and the Diagnostic Boundaries of Bipolar Disorder in Youths. *American Journal of Psychiatry* 168:129-142. doi:10.1176/appi.ajp.2010.10050766
35. US Preventive Services Task Force (1996) Guide to clinical preventive services. In: *Quality AfHRa* (ed). Washington (DC),
36. Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O'Connor B, Majumdar A, Verley J, Hoffman MT, Massetti GA, Burrows-MacLean L, Fabiano GA, Waschbusch DA, Chacko A, Arnold FW, Walker KS, Garefino AC, Robb JA (2008) The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. *J Child Adolesc Psychopharmacol* 18 (6):573-588. doi:10.1089/cap.2008.065
37. Waxmonsky JG, Wymbs FA, Pariseau ME, Belin PJ, Waschbusch DA, Babocsai L, Fabiano GA, Akinnusi OO, Haak JL, Pelham WE (2013) A novel group therapy for children with ADHD and severe mood dysregulation. *Journal of attention disorders* 17 (6):527-541. doi:10.1177/1087054711433423
38. Fabiano GA, Pelham WE, Gnagy EM, Burrows-MacLean L, Coles EK, Chacko A, Wymbs BT, Walker KS, Arnold F, Garefino A, Keenan JK, Onyango AN, Hoffman MT, Massetti GM, Robb JA (2007) The single and combined effects of multiple intensities of behavior modification and

1 methylphenidate for children with attention deficit hyperactivity disorder in a classroom  
2 setting. *School Psychol Rev* 36 (2):195-216

3 39. Pelham WE, Greiner A, Gnagy EM (1997) Children's Summer Treatment Program Manual.  
4 In: Inc (ed) *Comprehensive Treatment for Attention Disorders*. Buffalo, NY,

5 40. Krieger FV, Pheula GF, Coelho R, Zeni T, Tramontina S, Zeni CP, Rohde LA (2011) An open-  
6 label trial of risperidone in children and adolescents with severe mood dysregulation. *J Child*  
7 *Adolesc Psychopharmacol* 21 (3):237-243. doi:10.1089/cap.2010.0123

8 41. Parmar A, Vats D, Parmar R, Aligeti M (2014) Role of naltrexone in management of  
9 behavioral outbursts in an adolescent male diagnosed with disruptive mood dysregulation  
10 disorder. *J Child Adolesc Psychopharmacol* 24 (10):594-595. doi:10.1089/cap.2014.0072

11 42. Périssé D, Gerardin P, Cohen D, Flament M, Mazet P (2006) Conduct disorder in children  
12 and adolescents: a review of current therapeutic approaches. *Neuropsychiatrie de l'enfance*  
13 *et de l'adolescence* 54:401-410. doi:10.1016/j.neurenf.2005.09.006

14 43. Zhou X, Hetrick SE, Cuijpers P, Qin B, Barth J, Whittington CJ, Cohen D, Del Giovane C, Liu  
15 Y, Michael KD, Zhang Y, Weisz JR, Xie P (2015) Comparative efficacy and acceptability of  
16 psychotherapies for depression in children and adolescents: A systematic review and network  
17 meta-analysis. *World Psychiatry* 14 (2):207-222. doi:10.1002/wps.20217

18 44. MacPherson HA, Cheavens JS, Fristad MA (2013) Dialectical behavior therapy for  
19 adolescents: theory, treatment adaptations, and empirical outcomes. *Clinical child and*  
20 *family psychology review* 16 (1):59-80. doi:10.1007/s10567-012-0126-7

21 45. Goldstein TR, Fersch-Podrat RK, Rivera M, Axelson DA, Merranko J, Yu H, Brent DA, Birmaher  
22 B (2015) Dialectical behavior therapy for adolescents with bipolar disorder: results from a pilot  
23 randomized trial. *J Child Adolesc Psychopharmacol* 25 (2):140-149. doi:10.1089/cap.2013.0145

24 46. Mufson L, Sills R (2006) Interpersonal Psychotherapy for depressed adolescents (IPT-A): an  
25 overview. *Nordic journal of psychiatry* 60 (6):431-437. doi:10.1080/08039480601022397

26 47. Nelson-Gray RO, Keane SP, Hurst RM, Mitchell JT, Warburton JB, Chok JT, Cobb AR (2006) A  
27 modified DBT skills training program for oppositional defiant adolescents: promising  
28 preliminary findings. *Behav Res Ther* 44 (12):1811-1820. doi:10.1016/j.brat.2006.01.004

29 48. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH, Jr. (2002) Psychopharmacology and  
30 aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related  
31 behaviors in ADHD. *J Am Acad Child Adolesc Psychiatry* 41 (3):253-261. doi:10.1097/00004583-  
32 200203000-00004

33 49. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS (2006)  
34 Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. *J Can*  
35 *Acad Child Adolesc Psychiatry* 15 (1):27-39

36 50. Rust J, Golombok S (2009) *Modern Psychometrics. The science of psychological*  
37 *assessment*. 3 edn., London and New York

38 51. Leibenluft E, Stoddard J (2013) The developmental psychopathology of irritability. *Dev*  
39 *Psychopathol* 25 (4 Pt 2):1473-1487. doi:10.1017/s0954579413000722

40 52. Stringaris A, Goodman R, Ferdinando S, Razdan V, Muhrer E, Leibenluft E, Brotman MA  
41 (2012) The Affective Reactivity Index: a concise irritability scale for clinical and research  
42 settings. *J Child Psychol Psychiatry* 53 (11):1109-1117. doi:10.1111/j.1469-7610.2012.02561.x

43 53. Guile JM, Chapdelaine C, Desrosiers L, Cornez C, Bouvier H, Breton JJ (2009) Preliminary  
44 reliability study of the affective lability scale adapted for adolescents in a francophone  
45 clinical population. *J Can Acad Child Adolesc Psychiatry* 18 (4):293-306

46 54. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, McCague K, D'Souza J, Wamil  
47 A, Lehman RB, Berv D, Linden D (2006) A double-blind, randomized, placebo-controlled trial  
48 of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. *Am J*  
49 *Psychiatry* 163 (7):1179-1186. doi:10.1176/appi.ajp.2006.163.7.1179

50 55. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K,  
51 Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J (2007) Olanzapine  
52 versus placebo in the treatment of adolescents with bipolar mania. *Am J Psychiatry* 164  
53 (10):1547-1556. doi:10.1176/appi.ajp.2007.06111932

54 56. Cohen D, Consoli A, Bodeau N, Purper-Ouakil D, Deniau E, Guile JM, Donnelly C (2010)  
55 Predictors of placebo response in randomized controlled trials of psychotropic drugs for  
56 children and adolescents with internalizing disorders. *J Child Adolesc Psychopharmacol* 20  
57 (1):39-47. doi:10.1089/cap.2009.0047

58  
59  
60  
61  
62  
63  
64  
65

- 1 57. Cohen D, Deniau E, Maturana A, Tanguy ML, Bodeau N, Labelle R, Breton JJ, Guile JM  
2 (2008) Are child and adolescent responses to placebo higher in major depression than in  
3 anxiety disorders? A systematic review of placebo-controlled trials. *PloS one* 3 (7):e2632.  
4 doi:10.1371/journal.pone.0002632
- 5 58. Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP (2011)  
6 Deconstructing pediatric depression trials: an analysis of the effects of expectancy and  
7 therapeutic contact. *J Am Acad Child Adolesc Psychiatry* 50 (8):782-795.  
8 doi:10.1016/j.jaac.2011.04.004
- 9 59. Henry A, Kisicki MD, Varley C (2012) Efficacy and safety of antidepressant drug treatment  
10 in children and adolescents. *Mol Psychiatry* 17 (12):1186-1193. doi:10.1038/mp.2011.150
- 11 60. Efron D, Jarman F, Barker M (1997) Side effects of methylphenidate and dexamphetamine  
12 in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.  
13 *Pediatrics* 100 (4):662-666
- 14 61. Ingenhoven TJ, Duivenvoorden HJ (2011) Differential effectiveness of antipsychotics in  
15 borderline personality disorder: meta-analyses of placebo-controlled, randomized clinical  
16 trials on symptomatic outcome domains. *Journal of clinical psychopharmacology* 31 (4):489-  
17 496. doi:10.1097/JCP.0b013e3182217a69
- 18 62. Fonagy P, Speranza M, Luyten P, Kaess M, Hessels C, Bohus M (2015) ESCAP Expert Article:  
19 borderline personality disorder in adolescence: an expert research review with implications  
20 for clinical practice. *Eur Child Adolesc Psychiatry* 24 (11):1307-1320. doi:10.1007/s00787-015-  
21 0751-z
- 22 63. Dvir Y, Ford JD, Hill M, Frazier JA (2014) Childhood maltreatment, emotional dysregulation,  
23 and psychiatric comorbidities. *Harvard review of psychiatry* 22 (3):149-161.  
24 doi:10.1097/HRP.000000000000014
- 25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65




Table 1. Trials evaluating the benefit of psychotherapeutic interventions for youths with SMD or DMDD

Authors	Intervention Study design	Duration of study	N Recruitment	Age range (mean) Gender	Main diagnoses Inclusion criteria	Screening tools	Psychiatric comorbidities	Interventions and control	Scales for main outcomes (Mean at baseline)
Waxmonsky et al. 2008 [36]	BMOT Secondary analysis of RCT-DB vs. TAU with cross-over	Intervention: 9 weeks	33 Recruited from schools, health-care providers and public advertisements	5-12 y.o. (8.0) Boys 82%	ADHD youths meeting criteria for SMD and manic-like sympt. treated with different doses of MPH	NIMH criteria for SMD (items from the CBCL, DISC) + Manic-like sympt YMRS (+12) CGI-S (+3)	ADHD 100% ODD 72% CD 24% Depressive sympt. (CDRS-R>28) 72%	BMOT 3 weeks each sessions: no, low intensity, high intensity	YMRS (23.7) CDRS-R (35) IRS (5.0) DBD
Waxmonsky et al. 2013 [37]	Behavioral parenting training Pilot monocentric RCT open-label vs. TAU	Intervention: 9 weeks Follow-up: 16 weeks	7 Recruited from an outpatient clinic	7-12 y.o. (8.7) Boys 100%	ADHD (combined subtypes) youths meeting criteria for SMD treated with MPH	NIMH criteria for SMD (depression and mania items from the WASH-U-KSADS)	ADHD 100% ODD - NA CD - NA SAD 29%	CBT+ BPT behavioral parental training 105-minute concurrent parent and child meetings	YMRS (23.7) CDRS-R (35) DBD CGAS APQ
Stoddard et al. [13]	IBT-SMD Pilot monocentric non-controlled open-label	Intervention: 6 days Follow-up: 2 weeks	14 NA	8-18 y.o. (14.1) Boys: 47%	Lifetime diagnosis of DMDD and clinically significant DMDD symptoms (CGI-S $\geq$ 3)	DSM-5 criteria for DMDD	ADHD 71% ODD 100% ANX 71% MDD 14%	4 sessions of the active training IBT task	Parent- and self-report ARI SCARED STAXI-2 C/A CDI "Balance point" as a cognitive marker of angry judgment bias

<a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> NCT01862549 USA (Cornell University)	DBT-C Pilot monocentric RCT open-label vs. TAU	Intervention: 32 weeks Follow-up: 12 weeks	60 (target sample) NA	7-12 y.o. Both genders	DMDD youths may be medicated if stabilized for at least 6 weeks	DSM-5 criteria for DMDD	NA	2 pre-treatment and 24 treatment sessions, once per week (30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both)	CGI-I MSQ ERC ARI MAVRIC SSRS C-SSIS
<a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> NCT01591564 USA (Johns Hopkins University, NIMH)	IPT-SMD Pilot monocentric non-controlled open-label	Intervention: 16 weeks No follow-up	5 (target sample) NA	13-17 y.o. Both genders	SMD youths may be medicated if stabilized for at least 4 weeks + CGAS ≤ 60	NIMH criteria for SMD	NA	once per week; 16 weeks	CGI-I
<a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> NCT01962623 USA (Johns Hopkins University, NIMH)	IPT-MBD Pilot monocentric RCT-SB vs. TAU	Intervention: 24 weeks No follow-up	44 (target sample) NA	12-17 y.o. Both genders	SMD youths + CGAS ≤ 60 CGI-S ≥ 4	NIMH criteria for SMD	NA	once per week; 24 weeks	CGI-I
<a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> NCT02531893 USA (NIMH)	CBT vs. IBT Pilot monocentric open-label	Intervention: 10 weeks No follow-up	40 (target sample) NA	8-18 y.o. Both genders	DMDD, ADHD, ODD youths may be medicated (no delay period) + CGI-S ≥ 3	DSM-5 criteria	NA	4 sessions over 4 days and 8 weeks of weekly booster sessions	CGI-I ARI

BMOT: Behavior Modification therapy; RCT: Randomized controlled trial; DB: Double-blind; TAU: Treatment-as-usual; y.o.: year old; NA: Not Available; Sympt.: Symptoms; SB: Single-blind; MPH: Methylphenidate; CBCL: Child Behavior Checklist; DISC: Diagnostic Interview Schedule for Children; YMRS: the Young Mania Rating Scale; CDRS-R: the Children's Depression Rating Scale Revised; IRS: Impairment Rating Scale; DBD: Disruptive Behavior Disorders Rating Scale; WASH-U-KSADS: the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia; CGAS: the Children's Global Assessment Scale; APQ: the Alabama Parenting Questionnaire; MSQ: Mood Symptoms Questionnaire; ERC: Emotion Regulation Checklist; ARI: Affective Reactivity Index; MAVRIC: Measure of Aggression Violence and Rage in Children; SSRS: Social Skills Rating Scale; C-SSIS: Columbia Suicide and Self-Injury Severity Rating Scale; IBT: Interpretation Bias Training

Table 2. Trials evaluating the benefit of pharmacological treatments for youths with SMD or DMDD

Authors	Intervention Study design	Duration of study	N Recruitment	Age range (mean) Gender	Main diagnoses Inclusion criteria	Screening tools	Psychiatric comorbidities	Interventions and control	Scales for main outcomes	Main results
Waxmonsky et al. 2008 [36]	MPH Secondary analysis of RCT-DB vs. PBO with cross-over	Intervention: 9 weeks	33 Recruited from schools, health-care providers and public advertisements	5-12 y.o. (8) Boys 82%	ADHD youths meeting criteria for SMD and manic-like sympt.treated with different intensity of psychotherapy	NIMH criteria for SMD (items from CBCL, DISC) + Manic-like sympt YMRS (+12) CGI (+3)	ADHD 100% ODD 72% CD 24% Depressive sympt. (CDRS-R>28) 72%	MPH 0.15 mg/kg, 0.3mg/kg, 0.6mg/kg	YMRS (23.7) CDRS-R (35) IRS (5.0) DBD	34% decrease in YMRS score 31% in CDRS-R score Improvement in externalizing symptoms Improvement in overall impairment
Dickstein et al. 2009 [24]	Lithium PRP, RCT-DB vs. PBO	Intervention: 6 weeks	25 Recruited via advertisements, on support groups' websites and via psychiatrists	7-17 y.o. (11.5) Boys 75%	SMD youths	NIMH criteria for SMD (K-SADS-PL with an additional SMD module)	ADHD 92% ODD 88% CD - NA MDD 20% SAD 12%	Lithium carbonate between 0.8-1.2 mEq/l	PANSS factor 4 YMRS (14.6) CDRS (29.8) CGI-S (4.9) CGAS (44.7) Conners' teacher OAS CGI-I	No significant differences in CGI-I or PANSS scores.
Krieger et al. 2011 [40]	Risperidone Pilot monocentric non-controlled open-label	Intervention:8 week Follow-up 8 weeks	21 Recruited via advertisements	7-17 y.o. (10.4) Boys 43%	SMD youths	NIMH criteria for SMD (K-SADS-PL with an additional SMD module)	ADHD 71% ODD 81% CD 14% MDD 14% AD 71%	Risperidone 0.5 to 3 mg/d (mean 1.28 mg)	ABC-Irritability (25.9) SNAP-IV (1.71) YMRS (12.7) CDRS (34.3) CGI-S (4.5) CGAS (46.9) MSQ (37.4) SCARED (34.7)	56% decrease in ABC-irritability 64% decrease in YMRS 34% decrease in CDRS 34% increase of CGAS
Parmar et al. 2014 [41]	Naltrexone Case report	3 months	1 inpatient	15 y.o. Boy	DMDD youths	DSM-5 criteria for DMDD	ADHD	Naltrexone 50mg/d	No	Significant improvement in aggressive symptoms



<a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> NCT01714310 USA (University of California, NIMH)	LDX combined or not with Fluoxetine Monocentric open-label period followed by RCT-DB vs. PBO	Intervention: 12 weeks (Open-label LDX: 4 weeks; CRT-DB Fluoxetine vs. PBO: 8 weeks) Follow-up period 4 weeks	50 (target sample) NA	7-17 y.o. Both genders	Youths with both SMD and ADHD criteria	NIMH criteria for SMD + inattentive or hyperactive/Impulsive subscales ADHD-RS>9 + ABC<12	NA	LDX low, medium, and high dose Fluoxetine	Safety/Efficacy CGI-I PARS CDRS ADHD-IV RS CSSS CALs R-MOAS ARI	NA
<a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> NCT00794040 USA (NIMH)	MPH combined or not with Citalopram PRP, Open-label period followed by RCT-DB vs. PBO	Intervention: 4-5 months Medication withdrawal PRP: 1 week Open-label MPH: 5 weeks CRT-DB Citalopram vs PBO: 8 weeks Open treatments phase: 10 weeks	160 (target sample) NA	7-17 y.o. Both genders	SMD youths	SMD + ADHD + CGAS ≤ 60	NA	Methylphenidate + Citalopram: 20-40 mg/d	Safety/Efficacy CGI-I ABC-Irritability	NA
<a href="http://www.clinicaltrials.gov">http://www.clinicaltrials.gov</a> NCT02063945 Israel (Sheba Medical Center)	Risperidone vs. Methylphenidate Open label randomized	Intervention: 8 weeks	70 (target sample) NA	5-18 y.o. Both genders.	ADHD youths with comorbid disruptive disorder (ODD/CD)	ADHD + ODD or CD or DMDD	NA	Methylphenidate (Ritaline LA <sup>®</sup> : 0.6 to 1.5 mg/kg/day; Concerta <sup>®</sup> : 1 to 2 mg/kg/day) vs. Risperidone (0.5 to 2 mg/day)	Safety/Efficacy R-MOAS CGI-I CGI-S ADHD-RS CDRS YMRS CSHQ	NA

PBO: Placebo; PRP: pre-randomization run-in period; PANSS: the Positive and Negative Syndrome Scale (factor 4= sum of excitement, hostility, uncooperativeness, and poor impulse control); OAS: Overt Aggression Scale; SNAP-IV: the Swanson, Nolan, and Pelham Scale-version IV; SCARED: Screen for Child Anxiety-Related Emotional Disorders; LDX: Lisdexamfetamine; PARS: the Pediatric Anxiety Rating Scale; ADHD-RS: the ADHD-IV Rating Scale; CSSS: the Columbia Suicide Severity Scale; CALS: the Children's Affective Liability Scale; R-MOAS: the Revised Modified Overt Aggression Scale; CSHQ: the Children Sleep Habits Questionnaire



Table 3. Trials evaluating the benefit of psychotherapeutic interventions for youths with SMD or DMDD

Authors	USPSTF's grade <sup>a</sup>	Main results	Limitations	Strengths
Psychotherapeutic studies				
Waxmonsky et al. 2008 [36]	Level II-1	34% decrease in YMRS score 31% in CDRS-R score Improvement in externalizing symptoms Improvement in overall impairment	<ul style="list-style-type: none"> <li>- Selected sample size (already enrolled in the STP study)</li> <li>- Use of psychometric instruments nonstandardized (YMRS for SMD criteria)</li> <li>- Only one assessment instrument for the measure of SMD/DMDD symptoms</li> <li>- Complex cross-over design (two within-subjects factors) not clear if change attributable to medication or psychotherapy</li> <li>- No procedures to evaluate treatment adherence</li> <li>- No follow-up evaluation of treatment effects</li> </ul>	<ul style="list-style-type: none"> <li>- Size of the sample</li> <li>- Description of the treatments detailed</li> <li>- Measure of tolerability provided</li> <li>- Teacher-report information</li> <li>- LOCF analysis</li> </ul>
Waxmonsky et al. 2013 [37]	Level II-3	Decrease in CDRS-R $d=1.17$ , YMRS $d=0.81$ , DBD (ADHD $d=0.30$ , ODD $d=0.26$ , CD $d=0.27$ ), C-GAS ( $d=2.17$ ) Decrease in parenting behavior (parental involvement $d=-0.37$ and inconsistent discipline $d=0.46$ )	<ul style="list-style-type: none"> <li>- Small sample size</li> <li>- Sample bias: only boys included, only combined subtype of ADHD</li> <li>- Use of psychometric instruments nonstandardized (YMRS for SMD criteria)</li> <li>- Only one assessment instrument for the measure of SMD/DMDD symptoms</li> <li>- Non-comparative design</li> <li>- No follow-up evaluation of treatment effects</li> </ul>	<ul style="list-style-type: none"> <li>- Ethnic diversity within sample</li> <li>- Assessment of comorbidity and respect of exclusion criteria (ASD, ID)</li> <li>- Description of the treatments detailed</li> <li>- Low level of drop-out rate among families</li> <li>- Measure of treatment fidelity</li> </ul>
Stoddard et al. [13]	Level II-3	Decrease of balance point (away from angry judgment bias) $\beta = 2.25$ morphs. CGI-I in the "slightly improved" range ( $d=0.59$ ) Decrease parent-report ARI score $\beta = -1.57$ points, no significant change in self-report ARI	<ul style="list-style-type: none"> <li>- Selected sample size (22% of the initial sample)</li> <li>- Possible sample bias, no information is provided about the recruiting method</li> <li>- Non-comparative design</li> <li>- Only four session of treatment are tested and follow-up evaluation was planned at 2 weeks</li> <li>- Symptom changes were modest and remained in clinical range, results on "balance point" is difficult to interpret</li> </ul>	<ul style="list-style-type: none"> <li>- Use of DMDD criteria</li> <li>- Use of two standardized psychometric instruments for the measure of DMDD symptoms (ARI, CGI-I)</li> <li>- Use of both parent and self-report information</li> <li>- Description of the treatments detailed</li> <li>- Measure of "balance-point" suggests possible mechanisms for treatment efficacy</li> </ul>

NCT01862549 USA	-	NA	<ul style="list-style-type: none"> <li>- Sample bias: only younger than 13 year olds</li> <li>- Assessors were not blinded</li> <li>- Lack of no-treatment control group</li> </ul>	<ul style="list-style-type: none"> <li>- Use of DMDD criteria</li> <li>- Randomization</li> <li>- Twelve-weeks follow-up evaluation of treatment effects</li> <li>- At least two assessment instrument for the measure of SMD/DMDD symptoms</li> <li>- Measure of compliance</li> </ul>
NCT01591564 USA	-	NA	<ul style="list-style-type: none"> <li>- Small sample size</li> <li>- Sample bias: only older than 13 year olds</li> <li>- Only one assessment instrument for the measure of SMD symptoms</li> <li>- Non-comparative design</li> <li>- No follow-up evaluation of treatment effects</li> </ul>	<ul style="list-style-type: none"> <li>- Measure of compliance</li> </ul>
NCT01962623 USA	-	NA	<ul style="list-style-type: none"> <li>- Lack of no-treatment control group</li> <li>- No follow-up evaluation of treatment effects</li> <li>- Only one assessment instrument for the measure of SMD symptoms</li> </ul>	<ul style="list-style-type: none"> <li>- Size of the sample (expected)</li> <li>- Randomization</li> <li>- Single-blind (Outcomes Assessor)</li> <li>- Measure of satisfaction</li> </ul>
NCT02531893 USA	-	NA	<ul style="list-style-type: none"> <li>- No follow-up evaluation of treatment effects</li> <li>- Assessors and participants were not blind</li> <li>- Findings from the arm with both forms of therapy with a 4 weeks wash-out periods would be difficult to interpret</li> <li>- Non randomized allocations of treatments</li> </ul>	<ul style="list-style-type: none"> <li>- Size of the sample (expected)</li> <li>- Diversity in terms of age, prescribed medication</li> <li>- Use of DMDD criteria</li> </ul>
Pharmacological studies				
Waxmonsky et al. 2008 [36]	Level II-1	34% decrease in YMRS score 31% in CDRS-R score Improvement in externalizing symptoms Improvement in overall impairment	<ul style="list-style-type: none"> <li>- Selected sample size (already enrolled in the STP study)</li> <li>- Use of psychometric instruments nonstandardized (YMRS for SMD criteria)</li> <li>- Only one assessment instrument for the primary outcome measure</li> <li>- Complex cross-over design (two within-subjects factors) not clear if change attributable to medication or psychotherapy</li> <li>- No procedures to evaluate treatment adherence</li> <li>- No follow-up evaluation of treatment effects</li> </ul>	<ul style="list-style-type: none"> <li>- Size of the sample</li> <li>- Description of the treatments detailed</li> <li>- Measure of tolerability provided</li> <li>- Teacher-report information</li> <li>- LOCF analysis</li> </ul>
Dickstein et al. 2009 [24]	Level II-1	No significant differences in CGI-I or PANSS scores.	<ul style="list-style-type: none"> <li>- Selected sample bias: community-based recruitment via advertisements, assessment of only a sample of those initially screened (<math>\approx 23\%</math>)</li> <li>- Use of psychometric instruments nonstandardized (YMRS for SMD criteria)</li> <li>- No comparison to a well-validated treatment</li> <li>- No follow-up evaluation of treatment effects</li> </ul>	<ul style="list-style-type: none"> <li>- Exclusion criteria and the prevalence of psychiatric comorbidity are detailed</li> <li>- Two-weeks placebo run-in period</li> <li>- Randomization</li> <li>- Assessors and participants were blind</li> <li>- Intent-to-treat analysis with LOCF</li> <li>- Measure of tolerability provided</li> </ul>

Krieger et al. 2011 [40]	Level II-2	56% decrease in ABC-irritability 64% decrease in YMRS 34% decrease in CDRS 34% increase of CGAS	<ul style="list-style-type: none"> <li>- Selected sample bias: community-based recruitment via advertisements, no current use of medication, little socio-economic diversity</li> <li>- Use of psychometric instrument nonstandardized (YMRS for SMD criteria)</li> <li>- Non-comparative design</li> </ul>	<ul style="list-style-type: none"> <li>- Exclusion criteria and the prevalence of psychiatric comorbidity are detailed</li> <li>- Description of the treatments detailed</li> <li>- At least two assessment instrument for the measure of SMD symptoms</li> <li>- Follow-up evaluation of treatment effects</li> <li>- Weekly measure of tolerability</li> </ul>
Parmar et al. 2014 [41]	Level II-3	Significant improvement in aggressive symptoms	<ul style="list-style-type: none"> <li>- Case report of a single case</li> <li>- Non-comparative design</li> <li>- No use of standardized psychometric instrument</li> <li>- No follow-up evaluation of treatment effects</li> </ul>	<ul style="list-style-type: none"> <li>- Use of DMDD criteria</li> </ul>
NCT01714310	-	NA	<ul style="list-style-type: none"> <li>- Selected sample bias: only ADHD youths</li> <li>- No procedures to evaluate the effect of Fluoxetine in naive participants (without Lisdexamfetamine)</li> <li>- No active-drug/placebo run-in period</li> <li>- Multiple scales used (risk of multiple statistical testing)</li> </ul>	<ul style="list-style-type: none"> <li>- Size of the sample (expected)</li> <li>- Randomization</li> <li>- Assessors and participants were blind</li> <li>- Measure of tolerability provided</li> </ul>
NCT00794040	-	NA	<ul style="list-style-type: none"> <li>- No procedures to evaluate the effect of Citalopram in naive participants (without Methylphenidate)</li> <li>- Only one assessment instrument for SMD symptoms</li> </ul>	<ul style="list-style-type: none"> <li>- Size of the sample (expected)</li> <li>- Randomization</li> <li>- Assessors and participants were blind</li> <li>- Pre-randomization phases (medication withdrawal period and 1-week placebo run-in period)</li> <li>- Measure of tolerability provided</li> </ul>
NCT02063945	-	NA	<ul style="list-style-type: none"> <li>- Selected sample bias: only ADHD youths with disruptive disorders</li> <li>- Use of psychometric instruments nonstandardized (YMRS, R-MOAS)</li> <li>- Assessors and participants were not blind</li> <li>- Lack of no-treatment control group</li> <li>- No active-drug/placebo run-in period</li> </ul>	<ul style="list-style-type: none"> <li>- Size of the sample (expected)</li> <li>- Randomization</li> <li>- Measure of tolerability provided</li> </ul>

Note: STP= Summer Treatment Program, NA = Not Available

<sup>a</sup> The level of evidence presented in each paper was categorized using the United States Preventive Services Task Force (USPSTF) criteria. Level I evidence denotes having at least one well-designed RCT supporting a treatment's possible efficacy. Level II-1 requires a well-designed controlled trial without randomization, level II-2 requires at least one well-designed cohort or case-control study, and level II-3 requires a multiple time series design. We excluded level III evidence (opinions of respected authorities based on clinical experience or descriptive studies) from our review.